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1 Beschreibung der Technologie  
und Stand der Einführung 
Der tragbare Kardioverter-Defibrillator (wearable cardioverter defibrillator/ 
WCD) ist eine neue Therapie in der primären und sekundären Prävention 
des plötzlichen Herzstillstands (sudden cardiac arrest/SCA). Der WCD wird in 
Form einer „LifeVest“ von der/dem Patientin/en für den Großteil des Tages, 
mit Ausnahme beim Duschen/Baden, getragen [1]. Derzeit ist nur ein WCD 
am Markt verfügbar: die LifeVest® der Firma ZOLL Medical Corporation, 
welche bereits in der fünften Geräte-Generation produziert wird. Das jüngste 
Modell, der WCD 4000, wurde 2011 in Europa mit der CE-Kennzeichnung 
zugelassen. Das Produkt erhielt bereits im Jahr 2001 eine FDA-Zulassung 
für Erwachsene und im Jahr 2015 auch eine für Kinder mit einem Risiko für 
SCA, die aufgrund bestimmter Erkrankungen oder fehlender Zustimmung 
der Eltern keine KandidatInnen für einen implantierbaren Kardioverter-De-
fibrillator (ICD) sind [2]. Der WCD soll einen vorübergehenden Schutz vor 
SCA in den Hochrisiko-Perioden zwischen der Diagnose oder Auftreten von 
ventrikulärer Tachykardie (VT) oder ventrikulärer Fibrillation (VF) und ei-
ner angemessenen Behandlung (oder deren Optimierung) bieten.  
Der WCD besteht aus zwei Hauptkomponenten:  
1. einem Elektrodengürtel und einer Weste, welche die Brust der/des 
Patientin/en umgeben und  
2. einem Monitor, welchen der/die PatientIn an der Taille oder an einem 
Schultergurt trägt. Der Monitor ist am Elektrodengurt angeschlossen 
und stellt digitalisierte EKG-Daten zur Verfügung, welche dann auf 
dem LifeVest® Network beobachtet werden können [3].  
Der WCD überwacht kontinuierlich das Herz des/der Patienten/in und gibt 
– wenn ein lebensbedrohlicher Herzrhythmus wie eine VT der VF erkannt 
wird – einen automatischen Behandlungsschock ab. Vor jedem Behandlungs-
schock wird ein Alarm ausgelöst, der von dem/der PatientIn durch Drücken 
von zwei Antworttasten, die sich am tragbaren Monitor befinden, verhindert 
oder zurückgehalten werden kann. Der WCD kann auf verschiedene VT- oder 
VF-Zonen programmiert und auf unterschiedliche Zeit und Schock-Energien 
(zwischen 75 und 150 Joules, biphasisch) eingestellt werden [4]. Ein Einzel-
schockereignis dauert in der Regel weniger als eine Minute.  
Das LifeVest® System ist für PatientInnen älter als 18 Jahre indiziert, die ein 
Risiko für SCA haben und keine KandidatInnen für einen implantierbaren 
Kardioverter-Defibrillator (ICD) sind, oder diesen ablehnen [3]. Der WCD 
ist derzeit für den Einsatz in Europa, den Vereinigten Staaten von Amerika, 
Australien, Israel, Japan und Singapur zugelassen. Weiters ist der WCD in 
Kanada und China zugelassen, dort aber noch nicht eingeführt. Der WCD 
wird für bestimmte Indikationen in Frankreich, Luxemburg und der Schweiz 
vollständig rückerstattet. Die erwarteten jährlichen Anwendungen des WCD, 
basierend auf den aktuellen US-Daten, betragen 160 Verordnungen pro Jahr 
in Österreich, wenn die gleiche Verordnungspraxis wie in den USA angenom-
men wird.  
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2 Gesundheitsbedrohung  
plötzlicher Herzstillstand 
Lebensbedrohende Herzrhythmusstörungen (VT/VF) sind für die Mehrheit 
der SCAs verantwortlich: Diese schnellen Herzrhythmen entstehen in den 
unteren (Pump-)Kammern des Herzens, den Ventrikeln. Während VT ein 
schneller, aber regelmäßiger Herzrhythmus ist, ist VF unregelmäßig und un-
synchronisiert. Bei VF hört das Herz auf, Blut zu pumpen, was zum SCA und 
weiters naturgemäß zum Tod führt, wobei ein Überleben mit guter neurolo-
gischer Funktion bei einer kleinen Gruppe der PatientInnen möglich ist [3]. 
SCAs treten ohne Vorwarnung auf, und da die PatientInnen innerhalb von 
Sekunden das Bewusstsein verlieren, können diese nicht um Hilfe rufen. 
Weitere Ursachen von SCA sind langsame Herzfrequenz (Bradykardie), keine 
elektrische Herzaktivität (Asystolie) oder elektromechanische Dissoziation bei 
post-akutem Herzinfarkt (MI).  
Risikofaktoren, die mit SCA assoziiert sind, unterscheiden sich in jungen und 
älteren Menschen. Bei jungen Menschen überwiegen Myokarditis, Drogen-
missbrauch, Kanalopathien und Kardiomyopathien als Risikofaktoren; chro-
nisch degenerative Erkrankungen (koronare Herzerkrankung, Herzklappen-
erkrankungen und Herzversagen) sind dagegen Risikofaktoren in älteren 
Menschen [5]. Eine Dysfunktion des linken Ventrikels ist ein wichtiger Be-
stimmungsfaktor für das Risiko von SCA, wobei die Familiengeschichte, Di-
abetes Mellitus, Übergewicht und ein Herzfrequenz-Profil während des Trai-
nings die SCA-Bestimmungsfaktoren vielfältig und multifaktoriell machen 
[6]. Spezifische Risikofaktoren für VT/VF, welche SCA verursachen, werden 
von den jeweiligen Indikationen bestimmt. Landesweite Screenings für das 
Risiko von SCA sind selten, aber das Screening von Familien von SCA Be-
troffenen ist wichtig. In Europa kommt es etwa zu 350.000 SCAs pro Jahr, 
welche außerhalb des Krankenhauses auftreten [7]. In Österreich sterben rund 
15.000 Menschen pro Jahr an plötzlichem Herztod [8].  
 
Behandlungsalternativen 
Abhängig von der Indikation kommen vier Arten von Standardbehandlungen 
bei ventrikulären Arrhythmien (VA) und zur Verhinderung von SCA zum 
Einsatz [5, 9]:  
 ICDs haben die Befähigung, die meisten Arrhythmien zu korrigieren 
und Schrittmacherfunktion auszuüben. Die Akkulaufzeit von ICDs be-
trägt sechs bis zehn Jahre, und ICDs können transvenös oder subku-
tan implantiert werden [10]. 
 (Guideline-basierte) Pharmakologische Therapien (antiarrhythmische 
Medikamente) zum Management von VAs sind a) Antiarrhythmika, 
b) Elektrolyte, oder c) andere Medikamente, die das Reverse-Remo-
deling verbessern und/oder welche zur Verringerung der Häufigkeit 
koronarer thrombotischer Verschlüsse beitragen [5]. 
 (Guideline-basierte) Katheter-(Radiofrequenz)Ablation ist ein Verfah-
ren, das eine Reihe von dünnen und flexiblen Kathetern (Drähten) 
umfasst, welche über den Hals, die Leiste oder den Arm in ein Blut-
gefäß zum Herzen des/der Patienten/in geführt werden. Die Katheter 
führen Wärmeenergie, welche jene Bereiche des Herzens zerstören, wo 
abnorme Herzschläge Arrhythmien verursachen [5]. 
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 Automatisierte externe Defibrillatoren (AEDs) können sowohl zu Hau-
se, als auch an öffentlichen Orten und/oder von medizinischem Not-
fallpersonal bei der Reanimation benutzt werden [5].  
 
 
3 Methoden 
Das Ziel des vorliegenden Berichts ist, die Evidenz über die Wirksamkeit 
und Sicherheit von WCD in der Primär- und Sekundärprävention von SCA 
bei Erwachsenen über 18 Jahren (gemäß CE-Kennzeichnung) und pädiatri-
schen PatientInnen (außerhalb der CE-Kennzeichnung) zusammenzufassen. 
Spezifische Indikationen sind im Scope des englischsprachigen Berichts zu 
finden.  
Die Evidenzsynthese wurde im Rahmen eines „Collaborative Assessments“ im 
Projekt EUnetHTA durchgeführt: Die Auswahl der „Assessment Elements“ 
für diesen Bericht basierte auf der EUnetHTA Core Model® Applikation für 
„Rapid Relative Effectiveness Assessments (REA) (4.2)“ [11]. Eine systema-
tische Literatursuche erfolgte am 14. Juli 2016 in den Datenbanken Medline 
über Ovid, Embase, Cochrane Library und CRD (DARE, NHS-EED, HTA). 
Zum Zeitpunkt der systematischen Literatursuche wurde keine Einschrän-
kung bezüglich Studiendesign angewandt. Darüber hinaus wurde eine Hand-
suche nach Literatur (Web-Suche) durchgeführt. Die systematische Litera-
tursuche wurde des Weiteren durch eine „Scopus-Suche“ ergänzt. Zusätzlich 
wurde der Hersteller (ZOLL Medical Corporation) kontaktiert und gebeten, 
ein Dossier einzureichen. Klinische Studienregister (ClinicalTrials.gov und 
die International Clinical Trials Registry Platform (ICTRP)) wurden durch-
sucht, um laufende klinische Studien oder Beobachtungsstudien zu identifi-
zieren. Zusätzlich wurde eine Guideline-Suche (G-I-N, National Guidelines 
Clearinghouse, TRIP-Datenbank und Handsuche) durchgeführt. 
Zur Beurteilung der Qualität der Fallserien wurde ein dafür entwickeltes Qua-
litätsbeurteilungsinstrument für prospektive Studien ohne Kontrollgruppe ver-
wendet [12]; die Bewertung der Evidenz erfolgte mittels „Grading of Recom-
mendations, Assessment, Development and Evaluation” (GRADE) [13]. 
Alle Arbeitsschritte wurden von zwei AutorInnen (des LBI-HTA) unabhängig 
voneinander durchgeführt und von den Ko-Autorinnen überprüft: Durchsicht 
der Abstracts gemäß des Scopes dieses Berichts und den vordefinierten Ein- 
und Ausschlusskriterien; Durchsicht der ausgewählten Volltexte für die Be-
reiche Wirksamkeit und Sicherheit; Kontrolle der Extraktionstabellen; Be-
wertung der Qualität der eingeschlossenen Studien sowie die Bewertung der 
Evidenz nach GRADE [13]. Eventuelle Meinungsverschiedenheiten wurden 
durch Diskussion gelöst.  
Für die Bereiche Beschreibung der Technologie und des Gesundheitsprob-
lems wurde relevante Literatur aus der systematischen Literatursuche und des 
Dossiers verwendet, gefolgt von einer Handsuche. Für die Bereiche Ethik, 
organisatorische, soziale und legistische Aspekte wurde einschlägige Literatur 
aus der systematischen Literatursuche herangezogen, gefolgt von einer Hand-
suche. Für diese Informationen wurde kein Qualitätssicherungsinstrument 
verwendet; es wurden jedoch mehrere Quellen herangezogen, um einzelne, 
möglicherweise voreingenommene, Quellen zu validieren. 
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Zusätzlich wurde eine semi-strukturierte Fokusgruppendiskussion mit Pati-
enten – potentiellen Kandidaten für den WCD – geführt: Ziel der Fokusgrup-
pe war, PatientInnen im Scoping zu beteiligen, um mögliche, vernachlässig-
te Endpunkte zu identifizieren und um die Möglichkeit der Verwendung des 
WCD zu evaluieren. Weiters zielte die Patientenbeteiligung auf die Beant-
wortung von Fragen zu ethischen, organisatorischen, sozialen und legistischen 
Aspekten ab. Die Fokusgruppe (in deutscher Sprache) wurde von einer Ex-
pertin für Patientenbeteiligung moderiert. Die Aufzeichnungen wurden (nach 
Zustimmung der Teilnehmer) transkribiert, anonymisiert und mittels einer 
Framework- Analyse analysiert [14]. Die Extraktion patientenrelevanter End-
punkte (Clustering/Charting) erfolgte durch eine Autorin und wurde von ei-
ner zweiten Autorin überprüft. Laut dem österreichischen Ethik-Komitee war 
kein Ethikantrag erforderlich. 
 
 
4 Ergebnisse 
Verfügbare Evidenz, Komparatoren, Endpunkte 
Keine Studie erfüllte die Studieneinschlusskriterien für die Beurteilung der 
klinischen Wirksamkeit des WCD: nur kontrollierte Vergleichsstudien (RCTs 
und nicht-randomisierte CTs) wurden für den Einschluss in Betracht gezogen. 
In der systematischen Literatursuche konnten keine kontrollierten Vergleichs-
studien identifiziert werden. Die Studieneinschlusskriterien für die Bewer-
tung der Sicherheit erlaubten neben kontrollierten Vergleichsstudien auch 
das Heranziehen prospektiver Studien ohne Kontrollgruppe (interventionelle 
einarmige Studien, Fallreihen und Registerstudien). Die systematische Lite-
ratursuche identifizierte eine prospektive interventionelle einarmige Studie 
[15], zwei prospektive Fallreihen [16, 17] und zwei prospektive Registerstu-
dien [18, 19], die den Studieneinschlusskriterien entsprachen.  
Es wurde keine Mindestanzahl an PatientInnen innerhalb einer Studie als 
Einschlusskriterium für die Beurteilung der klinischen Wirksamkeit oder 
Sicherheit verwendet. Einzelfallberichte wurden jedoch ausgeschlossen. Zu-
sätzlich wurden – laut dem EUnetHTA Core Model® 3.0 [20] – qualitative 
Studien für ethische, organisatorische, soziale und legistische Bereiche ein-
geschlossen. 
Die Komparatoren wurden auf Basis von Informationen aus relevanten ver-
öffentlichten klinischen Leitlinien zum Management des Risikos von SCA 
[5] und gemäß der EUnetHTA Leitlinien [21] ausgewählt. Sie umfassen ICD, 
Guideline-basierte pharmakologische Therapie, Radiofrequenz (Katheter) Ab-
lation und an öffentlichen Orten angebrachte externe Defibrillatoren (AED).  
Zur Beurteilung der klinischen Wirksamkeit wurden Mortalität (all-cause) 
und krankheits-spezifische Mortalität als primäre Endpunkte gewählt. Als se-
kundäre Endpunkte wurden Inzidenz von VT oder VF, angemessene Schocks, 
zurückgehaltene Schocks, die Vermeidung von ICD-Implantation, gesund-
heitsbezogene Lebensqualität (HRQoL), Hospitalisierungsrate, Zufriedenheit 
mit der Technologie und Compliance verwendet.  
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Zur Beurteilung der Sicherheit wurden unerwünschte Ereignisse (AE) wie 
Hautausschlag und Juckreiz, Fehlalarme, Herzklopfen, Benommenheit, Ohn-
macht, und Abbruch wegen Komfort- und Lifestyle-bezogener Beeinträchti-
gungen ausgewählt. Als schwerwiegende unerwünschte Ereignisse (SAE) wur-
den unangemessene und nicht erfolgreiche Schocks definiert.  
 
Klinische Wirksamkeit 
Keine Studie erfüllte die Studieneinschlusskriterien für die Beurteilung der 
klinischen Wirksamkeit des WCD.  
 
Sicherheit 
Es wurde keine Evidenz gefunden, um die Forschungsfrage hinsichtlich des 
Vergleichs des WCD mit Komparatoren zu beantworten. Die folgenden AEs 
wurden in den einarmigen Studien angegeben: Hautausschlag und Juckreiz 
(6 % der PatientInnen) [15], falsche Alarme (14 % der Patientinnen) [16], Herz-
klopfen, Benommenheit und Ohnmacht (9 % der PatientInnen) [18] und Ab-
bruch wegen Komfort- und Lifestyle-bezogener Beeinträchtigungen (16-22 % 
der PatientInnen) [15, 18]. Zwei Studien gaben an, dass 2 % [15] bzw. 0,5 % 
[19] der PatientInnen unangemessene Schocks (definiert als „nicht-VT/VF“ 
– klassifizierte Episoden, die dennoch durch einen WCD-Schock behandelt 
wurden [19]) erfahren hatten, während die verbleibenden drei Studien keine 
unangemessenen Schocks berichteten. Eine Studie zeigte, dass 0,7 % der Pa-
tientInnen [15] erfolglose Schocks aufgrund fehlerhafter Platzierung der The-
rapie-Elektroden erlebt hatten. Drei Studien berichteten über keine erfolg-
losen Schocks [16, 17, 19] und eine Studie machte keine Angaben zu diesem 
Endpunkt. Alle fünf Studien berichteten über die Häufigkeit der SAEs, wel-
che zum Tod führten, wobei diese in einer Studie auftraten (0,3 %) [15] (sie-
he Tabelle 1). 
 
Laufende Studien  
Derzeit laufen zwei RCTs, von denen erwartet wird, dass sie robuste klinische 
Daten liefern. Beide RCTs verwenden eine Standardbehandlung als Kompa-
rator. Eine Studie soll im Dezember 2017 (2.300 PatientInnen mit ventriku-
lärer Dysfunktion unmittelbar nach MI) und die andere im Oktober 2019 
(2.600 PatientInnen im Endstadium einer Nierenkrankheit, die mit Hämo-
dialyse beginnen) abgeschlossen werden.  
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Tabelle 1: Summary table of benefits and harms of WCD therapy for prevention of SCA 
 Health benefit** Harm 
 Mortality Incidence 
of VT/VF 
Avoidance  
of ICD 
implantation 
(Health-
Related) QoL 
Hospitalisation 
rate 
Satisfaction Compliance SAEs AEs 
WCD No 
evidence 
available 
No 
evidence 
available 
No  
evidence 
available 
No  
evidence 
available 
No  
evidence 
available 
No 
evidence 
available 
No 
evidence 
available 
Inappropriate shocks: 
2 % of patients [15] and 
0.5 % of patients [19], 
0 % of patients [16-18] 
Unsuccessful shocks: 
0.7 % of patients [15], 
0 % of patients  
[16, 17, 19] 
Frequency of SAEs 
leading to death: 0.3 % 
of patients [15], 0 % of 
patients [16-19] 
Skin rash and itching: 
6 % of patients [15] 
False alarms:  
14 % of patients [16] 
Palpitations, 
lightheadedness and 
fainting:  
9 % of patients [18] 
Discontinuation of WCD 
use due to comfort and 
lifestyle issues:  
22 % of patients [15] and 
in 16 % of patients [18] 
Quality of body 
of evidence+  
       Very low Very low 
Abbreviations: AE-adverse event; ICD-implantable Cardioverter Defibrillator; QoL-quality of life; SEA-serious adverse event; VT-Ventricular Tachycardia; VF-Ventricular Fibrillation.  
+ Quality of body of evidence according to GRADE-methodology was classified as follows: high (i.e. „Further research is very unlikely to change our confidence in the estimate of effect”); moderate 
(i.e. „Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate”); low (i.e. „Further research is very likely to have an important 
impact on our confidence in the estimate of effect and is likely to change the estimate”); very low (i.e. „Any estimate of effect is very uncertain”). 
** Further information can be found in the discussion of clinical effectiveness domain 
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5 Diskussion 
Da derzeit keine vergleichenden Studien vorliegen, kann keine Aussage zur 
Wirksamkeit gegenüber einer Standardtherapie hinsichtlich der Endpunkte 
Gesamtmortalität und/oder krankheitsbezogene Mortalität getroffen werden. 
Aber auch die Ergebnisse der prospektiven Beobachtungsstudien lassen auf-
grund der niedrigen Fallzahl in drei der fünf Studien [16-18], aufgrund des 
Fehlens jeglicher Komparatoren und aufgrund der Vielfalt der Indikationen 
der eingeschlossenen Patientengruppen in allen fünf Studien keine Aussagen 
zu. In Abwesenheit von Informationen über die Langzeitmortalität (>1 Jahr) 
der in den Studien eingeschlossenen PatientInnen ist die beobachtete Verbes-
serung der linksventrikulären Ejektionsfraktion (LVEF) (d. h. Verbesserung 
um 5-22,5 % Mittelwert/Median) [16-18] in Frage zu stellen, da sich diese im 
Laufe der Zeit ändern kann.  
Darüber hinaus gab es in keiner der fünf Studien Informationen über histo-
rische Kontrollen von SCA in den verschiedenen Patientengruppen, womit 
ein Vergleich zur potentiellen Vermeidung von SCA angestellt werden hätte 
können. Der WCD zeigte einen geringen Einfluss auf die Behandlung von 
SCA, weniger als 2 % der PatientInnen hatten angemessene Schocks [22]. Nur 
eine von fünf Studien zeigte die Vermeidung von ICD-Implantation bei Pa-
tientInnen, welche eine Indikation für einen ICD vor der WCD-Anwendung 
hatten [19]. Bei den vorliegenden Registerstudien fehlten einige wichtige In-
formationen, wie das verwendete Gerätemodell, die Einstellungen des Moni-
tors, wie oft die Antworttaste gedrückt wurde, die Anzahl der falschen Alarme, 
mögliche Geräte-Interaktionen, Informationen darüber, ob ein ICD zu Beginn 
der WCD-Anwendung indiziert war und möglicherweise vermieden wurde, 
sowie Informationen über die Schwere der Erkrankung bei Studieneinschluss 
(wie weit fortgeschritten die Krankheit war). Daten über HRQoL und Zu-
friedenheit mit der Technologie wurden großteils nicht mit standardisierten 
Methoden erhoben.  
Im Hinblick auf die Sicherheit der LifeVest® ist der Mangel an Berichter-
stattung zu AEs und SAEs in den eingeschlossenen Studien zu diskutieren. 
Die berichteten AEs und SAEs waren möglicherweise nicht vollständig. Die 
Vermeidung von ICDs könnte für die Zahler relevanter sein als für Patien-
tInnen – dies zeigten die Ergebnisse der Fokusgruppe, wo Patienten ICDs be-
vorzugt hätten. Die Ergebnisse in Bezug auf erfolglose Schocks (bei 0-0,7 % 
der PatientInnen), unangemessene Schocks (bei 0-2 % der PatientInnen) so-
wie die Häufigkeit von SAEs als Todesursache (bei 0-0,3 % der PatientIn-
nen) waren homogen. Im Gegensatz dazu waren die Ergebnisse bezüglich 
angemessener Schocks (1,1 %-43 % der PatientInnen) heterogen. Dies zeigt, 
dass eine Risikostratifizierung von PatientInnen von hoher Relevanz ist. Wei-
tere Sicherheitsaspekte, die berücksichtigt werden müssen, waren das (uner-
wünschte) Einschreiten von BeobachterInnen und das Entstehen von Signal-
störungen durch fallende und sich verdrehende Körper, welche dann zu nicht-
erfolgreiche Schocks führen [23]. 
Prospektive Studien mit hoher Fallzahl und mit gut definierten Indikations-
gruppen sind notwendig, um jene Patientengruppe zu bestimmen, welche von 
der Intervention profitieren würde. Zwei laufende Studien, die Ende 2017 
resp. 2019 Ergebnisse vorlegen, werden neue Erkenntnisse bringen und ge-
gebenenfalls Aussagen zur Wirksamkeit machen können. 
Wirksamkeit  
bez. Mortalität:  
keine Aussage möglich 
 
in Beobachtungsstudien: 
Verbesserung der LVEF 
keine Information über 
historische Kontrollen 
zu SCA in verschiedenen 
Indikationsgruppen 
 
in Beobachtungstudien 
fehlen viele relevante 
Informationen  
Sicherheit:  
Mangel an 
Berichterstattung  
über AEs und SAEs 
 
Ergebnisse:  
erfolglose, 
unangemessene Schocks 
 
heterogene Ergebnisse 
zu angemessenen 
Schocks 
2 laufende RCTs  
werden Aussagen zur 
Wirksamkeit möglich 
machen 
Tragbare Kardioverter Defibrillator Therapie zur Primär- und Sekundärprävention von plötzlichem Herzstillstand 
12 LBI-HTA | 2016 
In den vorliegenden Studien wird weiters über die Passform der LifeVest® 
diskutiert, da bei einigen PatientInnen aufgrund des Körperbaus Probleme 
auftreten könnten [22]. Der maximale Brustumfang für PatientInnen, die den 
WCD tragen können, beträgt 144 cm, das Mindestgewicht 18,6 kg und der 
Mindest-Brustumfang 66 cm [1]. Darüber hinaus hat der WCD keine Schritt-
macherfunktion für eine Backup-Bradykardie-Stimulation oder für eine Anti-
Tachykardie-Overdrive-Stimulation [4, 23]. Der WCD zeigte auch eine mög-
liche Unverträglichkeit mit unipolaren Stimulationstechniken [24], und hin-
sichtlich des Wirkungsunterschiedes zwischen mono- und biphasischer Wel-
lenform scheint es keinen Unterschied in der Effektivität zu geben [25]. 
Die breite CE-Kennzeichnung, die keine konkreten Indikationen vorgibt, ist 
problematisch, da die Indikationsstellung unklar bleibt. Unklarheiten bei Ri-
sikogruppen, SCA-Prävalenz und bei Arten von Arrhythmien, die zu SCA füh-
ren, erschweren eine Risikostratifizierung. Diese wäre aber erforderlich, um 
festzustellen, welche PatientInnen am meisten vom WCD profitieren und wann 
dieser demnach verwendet werden sollte. Dies lässt dem WCD Raum, als ei-
ne „greifbare Versicherung“ zu dienen, die Sicherheit vermittelt, obwohl nur 
begrenzte Evidenz vorliegt. 
Die Rolle des WCD in der Behandlung, Prävention sowie im Management 
bestimmter PatientInnen, bei denen die Erstlinientherapie nicht erfolgreich 
ist oder die auf eine Therapie warten, muss noch geklärt werden. 
 
Übertragbarkeit der Evidenz 
Insgesamt ist die Evidenz bezüglich der Beurteilung der Sicherheit niedrig 
bis sehr niedrig. Vier Studien unterlagen einem hohen und die fünfte Studie 
einem sehr hohen Bias-Risiko [17]. Zu den methodischen Einschränkungen 
gehörten: keine aufeinanderfolgende Rekrutierung von StudienteilnehmerIn-
nen [15, 18, 19]; Unklarheit, ob die StudienteilnehmerInnen zu einem ähnli-
chen Zeitpunkt ihrer Krankheit in die Studie eingetreten sind [15, 19] oder 
dies nicht der Fall war [18]; keine Offenlegung von Interessenskonflikten oder 
Herkunft der finanziellen Unterstützung für die Studie [15, 17] und hoher 
Verlust an Follow-up [15]. Vier Studien wurden vom Hersteller ZOLL Medi-
cal Corporation finanziell gefördert, für die fünfte Studie war das Sponsoring 
unklar [17].  
Das Auftreten eines Selektionsbias ist wahrscheinlich, da Personen, die an 
einer Studie teilnehmen, eher daran interessiert und bereit sind, Anweisun-
gen zu befolgen und sich an diese zu halten, als reguläre PatientInnen. Die 
Fallserien waren anfällig für Selektionsbias, da PatientInnen aus einer be-
stimmten Population – d. h. im Krankenhaus – rekrutiert wurden, und daher 
möglicherweise nicht die durchschnittliche Bevölkerung (z. B. bzgl. Multimor-
bidität) repräsentieren. Aufgrund des Fehlens eines Komparators kann nicht 
ausgeschlossen werden, dass die Effekte durch andere Gründe hervorgerufen 
wurden (z. B. im Fall von Hautausschlag). 
Zusätzliche Unsicherheiten hinsichtlich der Übertragbarkeit der Evidenz sind: 
Drei Studien machten keine Angaben zur Altersgruppe [16, 17, 19]; Perso-
nen, die nicht von einem/einer BegleiterIn oder BetreuerIn täglich versorgt 
wurden, waren von der Teilnahme an der Studie ausgeschlossen [15]. Einige 
Betroffene leben jedoch ohne täglichen Kontakt zu anderen Menschen und 
müssen daher in der Lage sein, den WCD alleine zu bedienen und zu be-
nützen. Die Zielpopulation des WCD ist nicht klar definiert, was sich in der 
Vielfalt der Krankheitsgruppen in den eingeschlossenen Studien bemerkbar 
mögliche Probleme: 
Passform des WCD, 
keine Schrittmacher-
funktion des WCD 
Unklarheiten:  
SCA-Prävalenz, Arten 
von Arrhythmien, die  
zu SCA führen 
 
Risikostratifizierung 
notwendig! 
LifeVest®   
vermittelt Sicherheit 
Sicherheit: Evidenz 
niedrig bis sehr niedrig 
 
methodische 
Einschränkungen 
Selektionsbias sehr 
wahrscheinlich 
 
Fehlen von 
Komparatoren 
Zielpopulation des WCD 
und Risikofaktoren für 
SCA sind nicht  
klar definiert 
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machte. Das Risiko von SCA hat sich in den klinischen Untergruppen und 
auch innerhalb der Untergruppen unterschieden. Risikofaktoren für SCA sind 
nicht klar definiert, was die Auswahl der Indikationen für den WCD weiter 
erschwert. Um das Risiko für SCA zu ermitteln, können elektrophysiologische 
Tests nach einem MI und genetische Analysen durchgeführt werden [26]. Ei-
ne individuelle Patientendatenanalyse wäre eine Option, dieser Herausforde-
rung zu begegnen.  
 
 
6 Schlussfolgerung 
Da derzeit keine vergleichenden Studien vorliegen, kann keine Aussage zur 
Wirksamkeit gemacht werden. Im Hinblick auf die Sicherheit ist die Quali-
tät der Evidenz sehr gering. Studien deuten darauf hin, dass der WCD in der 
kurz- bis mittelfristigen Anwendung eine relativ sichere Intervention ist. Je-
doch sind mehr Daten und eine angemessenere Berichterstattung von AEs 
und SAEs erforderlich, um robuste Aussagen zur Produktsicherheit machen 
zu können. Um die Wirksamkeit und Sicherheit des WCDs evaluieren zu kön-
nen, werden RCTs benötigt – Ergebnisse von zwei laufenden RCTs werden 
erwartet. 
Aufgrund der breiten Palette von Indikationen bedarf es einer weitergehen-
den Risikostratifizierung, um eine effektive und kosten-effektive Nutzung des 
WCD zu gewährleisten. 
 
 
 
keine Aussage über 
Wirksamkeit 
 
Sicherheit: Qualität der 
Evidenz sehr gering 
 
Ergebnisse von  
2 RCTs abwarten 
Risikostratifizierung 
notwendig! 
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ETH Ethical analysis domain 
EU European 
FDA Food and Drug Administration 
GKV Interessenvertretung der gesetzlichen Kranken- und Pflegekassen 
GL Guideline 
GMDN Global Medical Device Nomenclature 
HAS Haute Autorité des Santé 
HRQoL Health Related Quality of Life 
HRS Heart Rhythm Society 
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hr(s) hour(s) 
HSA Health Sciences Authority 
HTA Health Technology Assessment 
ICD Implantable Cardioverter Defibrillator 
ICD International Classification of Diseases  
ID Identification 
J Joules 
LEG Legal aspects domain 
LVEF Left Ventricular Ejection Fraction 
LBBB Left Bundle Branch Block 
LQTS Long QT Syndrome 
LQTS3 Long QT Syndrome Type 3 
MeSH Medical Subject Headings 
MI Myocardial Infarction 
min(s) minute(s) 
mo(s) month(s) 
MOH Ministry of Health 
NICM Non-Ischaemic Cardiomyopathy 
NSTEMI on-ST-segment Elevation Myocardial Infarction 
NYHA  New York Heart Association 
ORG Organisational aspects domain 
PM Pacemaker 
PMDA Pharmaceuticals and Medical Devices Agency 
PPCM Peripartum Cardiomyopathy 
pre-op pre-operation 
pt(s) patient(s) 
PVC Premature Ventricular Complex 
QoL Quality of Life 
REA Relative Effectiveness Assessment 
RCT Randomised Controlled Trials 
RVOT Right Ventricular Outflow Tract 
SA-ECG Signal-Averaged ECG 
SAE Serious Adverse Events 
SAF Safety domain 
SCA Sudden Cardiac Arrest 
SCD Sudden Cardiac Death 
SD Standard Deviation 
SPECT Single-Photon Emission Computed Tomography 
SOC Patient and Social aspects domain 
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SQTS Short QT syndrome 
STEMI ST-segment Elevation Myocardial Infarction 
TdP Torsade de Pointes 
TEC Description and Technical Characteristics of Technology domain 
TEC Technology Evaluation Centre 
TGA Therapeutic Goods Administration 
TOE Transoesophageal Echocardiography 
V Ventricular 
VA Ventricular Arrhythmias 
VF Ventricular Fibrillation 
VT Ventricular Tachycardia 
WCD Wearable Cardioverter Defibrillator 
WPW Wolff-Parkinson-White 
yr(s) year(s) 
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SUMMARY 
Scope 
The aim of this collaborative assessment (CA) is to summarise the information on clinical 
effectiveness and safety of the wearable cardioverter defibrillator (WCD) therapy in primary and 
secondary prevention of sudden cardiac arrest (SCA) in adults over 18 years of age (according to 
CE mark) and paediatric patients (outside of CE mark) at risk. Specific indications are listed in 
the Scope. 
The comparators that have been chosen based on the information from relevant published clinical 
guidelines (GLs) [1] and according to the European Network for Health Technology Assessment 
(EUnetHTA) GLs [2], include implantable cardioverter defibrillator (ICD), GL directed 
pharmacological therapy, GL directed radiofrequency (catheter) ablation, and automated external 
defibrillators (AEDs) that are to be used in three settings: homes, public places, and/or used by 
medical emergency staff during resuscitation. 
For the clinical effectiveness domain (EFF), the primary outcomes were all-cause mortality and 
disease specific mortality. Secondary outcomes were incidence of ventricular tachycardia (VT) or 
ventricular fibrillation (VF) – appropriate shocks and withheld shocks, avoidance of ICD 
implantation, health-related quality of life (HRQoL), hospitalisation rate, satisfaction, and 
compliance. Study designs were randomised controlled trials (RCT) and prospective non-
randomised controlled trials (CT). 
For the safety domain (SAF), adverse events (AE) of skin rash and itching, false alarms, 
palpitations, light-headedness, fainting, and discontinuation due to comfort and lifestyle issues were 
chosen and for serious adverse events (SAE), inappropriate shocks and unsuccessful shocks 
were chosen. Study designs were RCTs, prospective non-randomised CTs, and prospective studies 
without a control group e.g. observational studies, case series, and registry studies. 
No minimum number of patients within a study was used as inclusion criteria for the assessment 
of clinical effectiveness or safety. However, individual case reports were excluded. Additionally, for 
Organisational, Ethical, Patient and Social, and Legal aspects (ETH, ORG, SOC, LEG), qualitative 
studies were included according to the EUnetHTA Core Model® 3.0 [3]. 
 
Introduction 
Description of technology and comparators 
The WCD represents a novel therapy in primary and secondary prevention of SCA. It is a 
defibrillation technology that is worn by the patient for most of the day, except when taking a 
bath/shower when the presence of a caregiver or a family member is recommendable [4]. 
Currently, there is only one WCD on the market, the LifeVest® WCD manufactured by ZOLL 
Medical Corporation, which has five generations. In the studies included in this assessment, the 
following device generations were used: WCD 2000, 3000, 3100, 4000. Hence, these device 
generations were analysed in this assessment. The latest model, WCD 4000 – CE marked in 
Europe in 2011, is the device described in the Technical Characteristics of Technology domain 
(TEC) as it is the only model currently offered in Europe. The WCD consists of two main 
components: (1) an electrode belt and garment that surrounds the patient’s chest, and (2) a 
monitor that the patient wears around the waist or from a shoulder strap. The electrode belt 
connects to the monitor and provides digitised ECG data available to be viewed on LifeVest® 
Network [5] (B0001). 
The WCD monitors the patient’s heart continuously and in case it detects a life-threatening heart 
rhythm that it can restore, such as VT or VF, it delivers an automatic treatment shock [5]. In case 
of an alarm triggered by a life-threatening heart rhythm, the conscious patient can prevent the shock 
by pressing two response buttons found on the monitor unit anytime during the treatment sequence. 
The WCD can be programmed to different VT or VF zones and can be adjusted to different times 
and shock energy (between 75 and 150 Joules (J), biphasic) [6]. A single shock event typically takes 
less than one minute (B0001). 
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There are four categories of standard treatments, depending on the indication, that are being re-
placed, postponed, bridged, or optimised by the introduction of a WCD for the management of 
ventricular arrhythmia (VA) and for the prevention of SCA [1, 7]:  
 ICDs, which have the capacity to correct most arrhythmias and provide backup 
bradycardia pacing and anti-tachycardia overdrive pacing have their battery life from six to 
ten years, and can be implanted transvenously or subcutaneously [8].  
 GL directed pharmacological therapy, which offers management of VAs via 
discontinuation of offending pro-arrhythmic drugs and appropriate anti-arrhythmic 
therapy that includes a) anti-arrhythmic drugs, b) electrolytes, or c) other drugs that 
improve reverse remodelling and drugs that are helpful for reducing the frequency of 
coronary thrombotic occlusions [1]. 
 GL directed catheter (radiofrequency) ablation, a procedure that involves a series of thin 
and flexible catheters (wires) that are inserted in a blood vessel via the patient’s neck, 
groin, or arm and guided to the heart. The catheters carry heat energy that destroys 
those areas of the heart where abnormal heartbeats cause arrhythmias [1]. 
 AEDs available at homes, public places, and/or used by medical emergency staff during 
resuscitation [1] (B0001). 
The LifeVest® system is indicated for patients 18 years of age and older who are at risk for SCA 
and are not candidates for or refuse an ICD [5]. The device first received an FDA approval in 2001 
and in 2015, it received the FDA approval also for children who are at risk for SCA, but are not 
candidates for an ICD due to certain medical conditions or lack of parental consent [9]. The WCD 
claims to offer temporary protection from SCA in high risk periods during diagnosis, or an 
experience of VT/VF, and the appropriate treatment (or optimisation of it) (A0020, B0002). 
 
Health problem 
The LifeVest® claims to reduce the risk of SCA by restoring the life-threatening VT/VF that are 
responsible for the majority of SCAs. Both of these rapid heart rhythms arise in the heart’s lower 
(pumping) chambers, the ventricles. While VT is a fast, but regular heart rhythm, VF is irregular  
and unsynchronised. When fibrillating, the heart stops pumping blood, which leads to SCA that 
naturally leads to death. Survival with good neurological function occurs in a small minority of 
patients [5]. SCAs occur without warning and because patients tend to lose consciousness 
within seconds, they cannot call for help. Further causes of SCA are slow heart rate (bradycardia), 
no cardiac electrical activity (asystole), or electromechanical dissociation post-acute MI, which the 
WCD cannot treat [1, 10] (A0002). 
The risk factors associated with SCA differ in young and old individuals, where there is a 
predominance of myocarditis and substance abuse, channelopathies and cardiomyopathies in the 
young, and chronic degenerative diseases in the old (coronary artery disease (CAD), valvular 
heart diseases and heart failure) [1]. Dysfunction of the left ventricle is a significant determinant of 
the risk of SCA, but family history, lifestyle (no smoking, sports, healthy diet), diabetes mellitus, 
obesity, and heart rate profile during exercise make the determinants diverse and multifactorial 
[11]. Particular risk factors for VT/VF caused SCA are determined by respective indications. 
Nationwide screening for the risk of SCA is rare, but the screening of families of SCA victims is of 
importance (A0003, A0024). 
In Europe, there are about 350 000 out of hospital SCAs per year [12] and in Austria, 
approximately 15 000 people are affected by sudden cardiac death (SCD) per year [13]. The 
expected annual prescription of WCD is 160 prescriptions per year in Austria, when assuming the 
same prescribing practice as in the US (A0007, A0023). 
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Methods 
The selection of assessment elements for this CA was based on the EUnetHTA Core Model® 
Application for Rapid Relative Effectiveness (REA) Assessments (4.2) [14]. The checklist for 
potential ETH, ORG, SOC, LEG aspects of the HTA Core Model® for rapid REA was filled in as 
well. A systematic literature search was performed on 14/07/2016 in Medline via Ovid, Embase, 
The Cochrane Library, and CRD (DARE, NHS-EED, HTA) databases and, at the time of the 
systematic literature search, no limitations to study design were applied. In addition, handsearch 
of literature (web-search) was performed. Furthermore, the systematic literature search was 
complemented by a “Scopus search”. 
The manufacturer (ZOLL Medical Corporation) was contacted by LBI-HTA to send a submission 
file and clinical trial registries were assessed for registered ongoing clinical trials or observational 
studies: ClinicalTrials.gov, International Clinical Trials Registry Platform (ICTRP). A separate GL 
search (G-I-N, National Guidelines Clearinghouse, TRIP-Database, and handsearch) was 
performed as well.  
Two authors (from LBI-HTA) reviewed and included/excluded abstracts independently from each 
other according to the scope. These two authors also included and excluded studies (full texts) for 
EFF and SAF independently from each other. Any disagreements were resolved through 
discussion. For TEC and Health Problem and Current Use of the Technology domain (CUR), 
relevant literature from the systematic literature search and the EUnetHTA submission file were 
used and followed by a handsearch. For ETH, ORG, SOC, LEG, relevant literature from the 
systematic literature search was used and followed by a handsearch for relevant qualitative 
studies in order to answer respective assessment element questions – furthermore results from the 
Focus group were incorporated here as well (see below). All steps were checked and verified by 
co-authors. 
“Quality appraisal tool for case series” document was used for prospective studies without a 
control group [15] and the assessment of strength of evidence was done using “Grading of 
Recommendations, Assessment, Development and Evaluation” – GRADE approach [16]. These 
steps were performed by two authors independently from each other (from LBI-HTA). Any 
disagreements were resolved by consensus. Co-Authors checked this step. For TEC and CUR, 
as well as for the ETH, ORG, SOC, LEG, no quality assessment tool was used, but multiple 
sources were used in order to validate individual, possibly biased, sources.  
Additional semi-structured Focus group interviews with patients were developed and questions were 
discussed among two researchers and a third one was consulted for an independent opinion. The 
aim was to involve patients in scoping to identify possible neglected outcomes and to evaluate the 
possibility of the WCD use. Furthermore, the patient involvement primarily aimed to help 
answering questions regarding ETH, ORG, SOC, LEG, but results were considered for use in 
other domains as well. The four-hour face to face meeting was moderated by a patient support 
expert who also helped with gathering patients for the Focus group. The meeting that was held in 
German was recorded and transcribed upon participants ’ consent. The anonymised transcript 
was analysed using framework analysis [17]. Extraction of patient-relevant endpoints 
(clustering/charting) was done by one author (from LBI-HTA) and checked by the second (from 
LBI-HTA). According to the Austrian Ethics Committee, no ethical approval was needed. 
 
Results 
Available evidence 
No study fulfilled the study inclusion criteria for assessing clinical effectiveness of the WCD. RCTs 
and non-randomised CTs were considered for inclusion, but could not be identified through the  
systematic literature search (see Figure 1: Flow chart).  
The study inclusion criteria for assessing safety differed from the ones for assessing clinical 
effectiveness. In addition to RCTs and non-randomised CTs, prospective studies without a control 
group (interventional single arm studies, case series, and registry studies) were considered for the 
assessment of safety. The systematic literature search (see Figure 1: Flow chart) identified one 
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prospective interventional single arm study [18], two prospective case series [19, 20], and two 
prospective registry studies [21, 22], which matched the study inclusion criteria. 
Clinical effectiveness 
No study fulfilled the study inclusion criteria for assessing clinical effectiveness of the WCD 
(D0001, D0005, D0006, D0011, D0016, D0012, D0013, D0017, D0010, D0023). 
 
Safety 
No evidence was found to answer the research question comparing the WCD with comparators, 
since none of the included studies had a control group. The following AEs were reported: skin 
rash and itching, false alarms, palpitations, light-headedness and fainting and discontinuation due 
to comfort and lifestyle issues. In terms of SAEs, inappropriate WCD therapy was defined as non-
VT/VF episodes detected and treated by a WCD shock [22]. Two studies indicated that 2% [18] 
and 0.5% [22] of patients respectively experienced inappropriate shocks, whereas the remaining 
three studies reported no inappropriate shocks. Unsuccessful shocks were reported in four out of 
five studies. One study indicated that 0.7% of patients [18] experienced unsuccessful shocks due 
to incorrect placement of the therapy electrodes. Three studies reported no unsuccessful shocks 
[19, 20, 22] and one study did not report on this outcome. All five studies reported on the outcome 
frequency of SAEs leading to death, where death occurred in one study (0.3%) [18] (C0008). See 
Table 1: Summary table of benefits and harms of WCD therapy for prevention of SCA. 
 
Upcoming evidence 
Two RCTs are already ongoing and are expected to yield robust clinical data. Both RCTs use 
conventional treatment as a comparator. One study aims to be completed in December 2017 
(2300 patients with ventricular dysfunction immediately following MI) and the other one in October 
2019 (2600 patients with end stage renal disease beginning haemodialysis). Prospective 
studies with long-term mortality measures including well defined disease groups are necessary in 
order to determine the patient group that would benefit most from the intervention. For the full list 
of ongoing trials, see Table 8: List of ongoing studies with WCD in Appendix 1. 
 
Reimbursement 
The WCD is currently approved for use in Europe, United States, Australia, Israel, Japan, and 
Singapore. It has regulatory approval, but is not yet launched in Canada and China. The WCD is 
fully reimbursed for particular indications in France, Luxemburg, and Switzerland; see Table 13: 
Summary of reimbursement recommendations in European countries for the technology in 
Appendix 2 (A0021).  
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Table 1: Summary table of benefits and harms of WCD therapy for prevention of SCA 
 Health benefit** Harm 
 Mortality Incidence 
of VT/VF 
Avoidance of 
ICD implantation 
HRQoL Hospitalisation 
rate 
Satisfaction Compliance SAEs AEs 
WCD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessment 
elements 
Comparator 
No 
evidence 
available 
 
 
 
 
 
 
 
 
 
 
 
 
 
(D0001) 
No 
evidence 
available 
 
 
 
 
 
 
 
 
 
 
 
 
 
(D0005), 
(D0006) 
No  
evidence 
available 
 
 
 
 
 
 
 
 
 
 
 
 
 
(D0023) 
No 
evidence 
available 
 
 
 
 
 
 
 
 
 
 
 
 
 
(D0012), 
(D0013) 
No  
evidence 
available 
 
 
 
 
 
 
 
 
 
 
 
 
 
(D0010) 
No 
evidence 
available 
 
 
 
 
 
 
 
 
 
 
 
 
 
(D0017) 
No 
evidence 
available 
 
 
 
 
 
 
 
 
 
 
 
 
 
(H0203) 
Inappropriate 
shocks:  
2% of patients [18] and 
0.5% of patients [22], 
0% of patients [19-21] 
Unsuccessful 
shocks:  
0.7% of patients [18], 
0% of patients  
[19, 20, 22] 
Frequency of SAEs 
leading to death: 
0.3% of patients [18], 
0% of patients [19-22] 
 
 
(C0008) 
 
Lacking 
Skin rash  
and itching:  
6% of patients [18] 
False alarms:  
14% of patients [19] 
Palpitations,  
light-headedness  
and fainting:  
9% of patients [21] 
Discontinuation of 
the WCD use due to 
comfort and lifestyle 
issues: 22% of 
patients [18] and in 
16% of patients [21] 
 
(C0008) 
 
Lacking 
Quality of body 
of evidence+  
  
 
   
 
Very low Very low 
Abbreviations: AE-adverse event; ICD-implantable Cardioverter Defibrillator; QoL-quality of life; SEA-serious adverse event; VT-Ventricular Tachycardia; VF-Ventricular Fibrillation.  
+
 Quality of body of evidence according to GRADE-methodology was classified as follows: high (i.e. “Further research is very unlikely to change our confidence in the estimate of effect”); moderate 
(i.e. “Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate”); low (i.e. “Further research is very likely to have an important impact 
on our confidence in the estimate of effect and is likely to change the estimate”); very low (i.e. “Any estimate of effect is very uncertain”). 
** Further information can be found in the Discussion of the EFF. 
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Discussion 
Concerning the technical characteristic of the technology, the issues discussed include problems 
with the device fitting, as some patients may not have a good fit due to body habitus [23]. The 
maximum chest circumference for patients wearing the WCD is 144cm, the minimum weight is 
18.6kg, and the minimum chest circumference is 66cm [4]. To date, the WCD has no pacing 
capabilities for backup bradycardia pacing or for anti-tachycardia overdrive pacing [6, 24]. The 
WCD has also shown a possible incompatibility with unipolar pacing technologies [25] and 
concerning the difference in effectiveness between mono and biphasic waveform, there does not 
seem to be any difference in effectiveness [26].  
With regard to health problem and current use, the issues discussed include problems with a broad 
CE mark definition that does not specify concrete indications and hence leaves room for broad 
use of the WCD. There is unclarity in terms of SCA prevalence, types of arrhythmias that lead to 
SCA, and the risk stratification needed in order to establish which patients would benefit most and 
therefore when the WCD should be used. This leaves room for the WCD to serve as a tangible 
insurance that provides security with limited evidence for it. The role of the WCD in treatment/ 
prevention as well as in the management of specific patients, in whom the first line therapy is not 
successful, needs to be clarified.  
Concerning the clinical effectiveness, issues discussed include problems with the impossibility of 
making valid statements whether mortality increased or decreased, due to small sample sizes in 
three studies [19-21], the lack of any comparators, and the variety of enrolled patient groups in all 
five included studies (for the assessment of safety). In the absence of information on long-term 
mortality (> 1 year) from prospective studies, the improvement in left ventricular ejection fraction 
(LVEF) outcome is questioned as the improvement may change over time. Furthermore, no 
information on historic controls of SCA in different patient groups was provided in any of the five 
studies in order to compare how many SCAs could have been avoided. The WCD was shown to 
have very little impact in the treatment of SCA, maximum of 2% of patients, who wore the 
LifeVest® received appropriate shocks in almost any cohort [23]. Only one study out of five 
clearly stated the avoidance of ICD implantation in patients who have been indicated for an ICD 
before WCD use [22]. The existing registry studies are lacking some important information such 
as device model used, settings of the monitor, how often the response button was used, number 
of false alarms, possible device-device interactions, information whether an ICD was indicated at 
the beginning of the WCD use and possibly be avoided after the WCD use, and information on 
disease status (how far advanced the disease is) at baseline. Data on HRQoL and satisfaction 
should be collected using standardised methods, and RCTs and non-randomised CTs should be 
pursued in order to provide a strong evidence base. 
With regards to safety the issues discussed include problems with the lack of reporting on AEs in 
the included studies. The named AEs and SAEs were relevant for patients, but some might have 
been missed. Avoidance of ICDs might be more relevant for payers than for patients according to 
the results of the Focus group, where patients favoured ICDs. There is homogeneity in results with 
regard to unsuccessful shocks (in 0-0.7% of patients), inappropriate shocks (in 0-2% of patients), 
and frequency of SAEs leading to death (in 0-0.3% of patients). In contrast, there is heterogeneity 
in appropriate shocks (1.1% to 43% of patients), which might show that risk stratification of patients 
is of utmost importance. Other safety issues are bystander interference and unsuccessful shocks 
caused by signal disruption due to falling and wedging bodies [24].  
 
Applicability of evidence 
Overall, the strength of evidence is low to very low for safety outcomes. Four of five studies were 
subject to high risk of bias, the fifth study to very high risk of bias [20]. The methodological 
limitations include: non-consecutive recruitment of study participants [18, 21, 22], unclear if 
entering the study at a similar point in the disease [18, 22], or clearly not fulfilling this criteria [21], 
non-reporting about competing interests or sources of support for the study [18, 20], and high loss 
to follow up [18]. Four studies were sponsored by the manufacturer ZOLL Medical Corporation 
and for the fifth study, sponsoring was unclear [20]. See Table 9: Risk of Bias – on study level. 
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Selection bias might have occurred since people who participate in a trial might be more eager to 
follow instructions and adhere to requirements than regular patients. Case series were vulnerable 
to selection bias since patients were drawn from a particular population i.e. the hospital, which may 
not appropriately represent the average population (e.g. multimorbidity, non-compliant personality 
traits). Due to the lack of a comparator exposed to the same array of intervening variables, effects 
seen may be due to intervening effects (e.g. in case of skin rash). 
Uncertainties about the applicability of evidence derive from the fact that three studies did not 
indicate an age range [19, 20, 22]. Not seen at least daily by a companion or caregiver was an 
exclusion criteria in one study [18]. In real life, some people might live alone without having 
contact with people on a daily basis, so they need to be able to use and handle the WCD on 
their own. The target population of the WCD is not clearly defined, which can be seen in the 
diversity of disease groups in the included studies. The risk of SCA differs across clinical 
subgroups and also within the reported subgroups – See Table 11: Summary table 
characterising the applicability of a body of studies. Risk factors for SCA are not yet well defined, 
which further complicates the selection of appropriate indications for the WCD. The assessment 
of different baseline risks of patients is important. In order to identify the risk for SCA, 
electrophysiological testing after myocardial infarction (MI) and genetic analysis could be applied 
[27]. An individual patient data analysis would be one option to counter this challenge. Risk 
stratification would be necessary.  
 
Conclusion 
According to the published data, no statement can be made about the device effectiveness. With 
regard to safety, the quality of the body of evidence is very low (see Table 10: GRADE 
assessment – on outcome level). Studies suggest that the WCD could be a relatively safe 
intervention in the short to medium term. However, more data and more adequate reporting of 
AEs and SAEs are needed in order to establish the device safety. For the sake of both 
effectiveness and safety, RCTs are needed – results of the two ongoing RCTs are awaited (see 
Table 8: List of ongoing studies with WCD in Appendix 1). 
Due to the wide range of indications, more research into risk stratification is needed in order to  
secure an effective and cost-effective usage of the WCD. 
The Focus group approach proved useful in Scoping as well as in identifying answers to 
questions raised in the HTA on the WCD therapy. Gathered results informed the inclusion of 
outcome measures relevant to the target group and revealed patients’ views on HRQoL. Lessons 
learned from this pilot project guide future HTAs in further improving patient involvement 
processes for European assessments within the EUnetHTA project. 
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1 SCOPE 
Description Project scope 
Population  Patients: adults over 18 years of age (according to CE mark) and paediatric 
patients (outside of CE mark) with the following indications: 
1. As a bridge to an ICD [28]; e.g. for: 
a) patients immediately after explantation of an ICD, if an immediate  
reimplantation of an ICD is not possible [29, 30], 
b) patients in whom an immediate implantation of an ICD is indicated,  
but not possible [29], 
1. due to temporary contraindications to an ICD, 
2. due to being post VT/VF on the waiting list for an ICD. 
2. Patients indicated for an ICD, who refuse implantation for personal or  
other reasons. 
3. As a bridge to optimal pharmacological therapy, or as a protection during 
pharmacological therapy optimisation when a heightened risk of SCD is 
present, but possibly resolvable over time or with treatment of left 
ventricular dysfunction; [29, 30] e.g. for patients with: 
a) ischaemic heart disease with envisaged or recent revascularization 
(90-day waiting period post revascularization with either CABG or PCI), 
b) newly diagnosed non-ischaemic dilated cardiomyopathy (NICM) in 
patients starting GL directed medical therapy, 
c) secondary cardiomyopathy (tachycardia mediated, thyroid mediated, 
etc.) induced arrhythmias (secondary to hypothermia, electrolyte 
imbalance, iatrogenic prolongation of the QT interval, etc.) in which  
the underlying cause is potentially treatable, 
d) with certain forms of structural heart disease associated with risk of 
malignant arrhythmias or primary electric disease and in those with 
significantly impaired left ventricular systolic function. 
4. “Watch and wait” strategy for patients at risk for SCA during diagnosis. 
5. Post MI and LVEF of ≤ 35%, as a bridge therapy “in situations associated 
with increased risk of death in which ICDs have been shown to reduce 
SCA, but not the overall survival such as within 40 d of MI” [1, 29].  
6. As a bridge to a heart transplant [1, 29]. 
Rationale: According to GLs (e.g. from the American Heart Association (AHA)) 
[31], there is a recommended waiting time in some situations before an ICD is 
indicated. A recovery of structural abnormality and an improvement of ventricular 
dysfunction could occur so that an ICD therapy may not be indicated anymore. 
Furthermore, a patient could have some contraindications (e.g. an infection) 
and therefore should not receive an ICD for some time, or an ICD needs to be 
(temporarily) explanted due to specific reasons. Thus a WCD could be used as 
a bridge to an ICD or to a heart transplant (in order to cover the waiting period) 
[7, 23, 32, 33]. 
ICD-10 codes: VT (I47.2), VF and flutter (I49.0), Cardiomyopathy (I42),  
Acute MI (I21) 
MeSH-terms: sudden cardiac arrest, ventricular tachycardia,  
ventricular fibrillation, myocardial infarction, myocardial revascularization,  
heart transplantation 
Intended use of technology: treatment (prevention) 
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Description Project scope 
Intervention  WCD/LifeVest® (WCD 2000, 3000, 3100, 4000 which have CE mark),  
from ZOLL (Lifecor) Medical Corporation, Pittsburgh, PA, USA. 
The WCD device consists of 2 components:  
 an electrode belt that fits within a lightweight garment worn  
on the patient’s chest 
 a monitor that the patient wears around the waist or from a shoulder strap 
MeSH-terms: (cardioverter-) defibrillator (external), electric countershock 
Comparison In primary and secondary prevention: 
 ICD, 
 GL directed pharmacological therapy, 
 GL directed catheter (radiofrequency) ablation, 
 External defibrillators to be used in three settings: homes, public places, 
and/or used by medical emergency staff during resuscitation. 
Rationale: Comparators have been chosen based on the information from 
relevant published clinical GLs [1] and according to the EUnetHTA GLs [2]. 
Outcomes Effectiveness: 
Primary endpoint: 
 Mortality (long term mortality), 
o All-cause mortality, 
o Disease-specific mortality. 
Secondary endpoints: 
 Incidence of VT/VF, 
 Avoidance of ICD implantation, 
 HRQoL, 
 Hospitalisation rate, 
 Satisfaction, 
 Compliance. 
Safety: 
 AEs, device related and patient related (frequency of AEs, what are these, 
frequency of discontinuation due to AEs, frequency of unexpected AEs),  
 SAEs, device related and patient related (frequency of SAEs, what are 
these, frequency of SAEs leading to death).  
Rationale: Outcomes have been selected based on the recommendations from 
relevant clinical GLs [1, 2, 32] and according to EUnetHTA GLs on Clinical and 
Surrogate Endpoints and Safety [34]. 
Study 
design 
Effectiveness: RCTs, prospective non-randomised CTs 
Safety: RCTs, prospective non-randomised CTs, prospective studies without  
a control group e.g. observational studies, case series, registry studies 
(manufacturer database). 
No minimum number of patients within a study was used for inclusion criteria 
for the assessment of clinical effectiveness or safety because there would have 
been the possibility of identifying smaller RCTs or CTs through the systematic 
literature search, which the authors did not want to exclude based on its small 
sample size. However, individual case reports were excluded. 
Organisational, ethical, patient and social, legal aspects: 
Qualitative studies (according to the EUnetHTA Core Model® 3.0) [3] 
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2 METHODS AND EVIDENCE INCLUDED  
2.1 Assessment Team 
Description of the distribution of responsibilities and the workload between authors and co-authors: 
 
LBI-HTA (1st authors): 
 Develop first draft of EUnetHTA project plan. 
 Perform the literature search. 
 Carry out the assessment: answer assessment elements, fill in checklist regarding  
potential ETH, ORG, SOC, LEG aspects of the HTA Core Model® for rapid REA. 
 Send “draft versions” to reviewers, compile feedback from reviewers and perform  
changes according to reviewers’ comments. 
 Prepare the final assessment and write the final summary of the assessment. 
 
AAZ (co-authors): 
 Review the draft EUnetHTA project plan. 
 Check and approve all steps (e.g. literature selection, data extraction,  
assessment of risk of bias). 
 Agree with 1st authors on the conclusions made. 
 Review the draft assessment, propose amendments where necessary  
(perform additional handsearch of literature if needed) and provide written feedback. 
 
2.2 Source of assessment elements 
The selection of assessment elements was based on the EUnetHTA Core Model® Application for rapid 
REA (4.2) [14]. The checklist for potential ETH, ORG, SOC, LEG aspects of the HTA Core Model® 
for rapid REA was filled in as well. Additionally, further assessment elements from the EUnetHTA Core 
Model® (3.0) [3] domains: ETH, ORG, SOC, LEG aspects – relevant for medical and surgical inter-
ventions – were included if deemed relevant. The selected issues (generic questions) were translated 
into actual research questions (answerable questions). Some assessment element questions were 
answered together i.e. questions were listed below each other and a summarised answer is provided. 
 
2.3 Search 
A systematic literature search was performed on 14/07/2016 in the following databases: 
 Medline via Ovid 
 Embase 
 The Cochrane Library 
 CRD (DARE, NHS-EED, HTA). 
At the time of the systematic literature search, no limitations to the study design were applied. In ad-
dition, handsearch of literature (web-search) was performed. Furthermore, the systematic literature 
search was complemented by a “Scopus search” (i.e. citation tracking); See Figure 1: Flow chart. 
The manufacturer (ZOLL Medical Corporation) was contacted by LBI-HTA on 10/05/2016, 
received the EUnetHTA submission file for medical devices on 06/06/2016, and sent the 
completed submission file back on 19/07/2016 (including some corrections sent on 26/07/2016). 
Clinical trial registries were assessed for registered ongoing clinical trials or observational studies: 
ClinicalTrials.gov, International Clinical Trials Registry Platform (ICTRP). 
A separate GL search (G-I-N, National Guidelines Clearinghouse, TRIP-Database, and handsearch) 
was performed as well. 
Detailed tables can be found in the Documentation of the Search Strategies in Appendix 1. 
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2.4 Literature selection and data extraction 
Literature selection: Two authors (from LBI-HTA) reviewed and included/excluded abstracts 
independently from each other according to the scope. These two authors also included and 
excluded studies (full texts) for assessment of clinical effectiveness and safety independently 
from each other (see Table 2. Main characteristics of studies included) – as defined in the scope. 
Any disagreements were resolved through discussion. For TEC and CUR, relevant literature from 
the systematic literature search and the EUnetHTA submission file were used and followed by a 
handsearch. For ETH, ORG, SOC, LEG, relevant literature from the systematic literature search 
was used and followed by a handsearch for relevant qualitative studies in order to answer 
respective assessment element questions. All steps were checked and verified by co-authors. 
Data extraction for EFF and SAF: One author extracted the data and a second controlled the 
extracted data (from LBI-HTA). Co-Authors checked and verified this step as well.  
 
2.5 Flow chart of study selection 
 
Figure 1: Flow chart 
 
After deduplication of systematic literature search, 601 bibliographic citations remained. By means 
of handsearch (including Scopus search), 139 citations were identified, which enhanced the total 
number of citations to 740 citations. The Scopus search added one citation for acquisition of full texts. 
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CLINICAL EFFECTIVENESS 
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2.6 Quality rating of studies 
All reporting of clinical effectiveness and safety data was done according to the Preferred Reporting 
Items for Systematic Reviews and Meta-Analyses (PRISMA Statement 2012) [35].  
The “Quality appraisal tool for case series” document was used for prospective studies without a 
control group [15]. Assessment of the strength of evidence was done using the “Grading of Re-
commendations, Assessment, Development and Evaluation” – GRADE approach [16]. These steps 
were performed by two authors independently from each other (from LBI-HTA). Any 
disagreements were resolved by consensus. Co-Authors checked and verified this step.  
For TEC and CUR, no quality assessment tool was used, but multiple sources were used in order 
to validate individual, possibly biased, sources. Descriptive analysis of different information sources 
was performed. The completed EUnetHTA submission file from the manufacturer was used as the 
starting point. 
For other domains (ETH, ORG, SOC, LEG), no quality assessment tool was used, but multiple 
sources were used in order to validate individual, possibly biased, sources. Descriptive analysis of 
different information sources was performed. 
Outcomes were selected based on the recommendations from relevant clinical GLs [1, 2, 32] and 
according to EUnetHTA GLs on Endpoints used in REA: Surrogate Endpoints [34]. Furthermore, 
outcomes were discussed among authors, co-authors, dedicated reviewers, and external experts. 
 
2.7 Description of the evidence used 
Table 2. Main characteristics of studies included  
Author and 
year or 
study name 
Study  
type 
Number of 
patients 
Intervention Main  
endpoints 
Included in clinical 
effectiveness and/ 
or safety domain 
Feldman 
2004 [18]  
(WEARIT/ 
BIROAD) 
Prospective 
intervention
al single 
arm study 
289  
(177 in 
WEARIT, 
112 in 
BIROAD) 
WCD Mortality (all-cause,  
disease specific), 
appropriate WCD 
shocks, unnecessary 
WCD shocks, AEs and 
SAEs 
Safety domain 
Duncker 
2014 [19] 
Prospective 
case-series 
12  
(7 treated 
with WCD) 
WCD Mortality (all-cause,  
disease specific), 
improvement in LVEF, 
incidence of VT/VF,  
incidence of syncope 
Safety domain 
Kondo  
2015 [20] 
Prospective 
case-series 
24 WCD Mortality (all-cause,  
disease specific), 
appropriate WCD 
shocks, SAEs, 
improvement in LVEF*, 
ICD implantation after 
WCD use 
Safety domain 
Kao  
2012 [21] 
(WIF) 
Prospective 
registry 
study 
89 (82 
completed 
the study) 
WCD Mortality (all-cause, 
disease specific), 
improvement in LVEF, 
WCD daily use in hrs 
(compliance with the 
WCD), AEs 
Safety domain 
Kutyifa  
2015 [22] 
(WEARIT-II) 
Prospective 
registry 
study 
2000 WCD Mortality (all-cause,  
disease specific), VT/VF 
events, improvement in 
LVEF, ICD implantation  
Safety domain 
*  They reported on these endpoints, which were not clearly stated in the introduction or methods section 
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Abbreviations: AE-Adverse Events; ICD-Implantable Cardioverter Defibrillator; LVEF-Left Ventricular Ejection Fraction; 
SAE-Serious Adverse Events; VF-Ventricular Fibrillation; VT-Ventricular Tachycardia; WCD-Wearable Cardioverter Defibrillator. 
For further information please see Table 7: Characteristics of included studies in Appendix 1. 
2.8 Patient involvement 
Patients were involved in scoping in order to understand the patient’s perspective, to identify 
possible neglected outcomes and to evaluate the possibility of WCD use. Furthermore, relevant 
results were incorporated in the assessment element domains as appropriate. A standardised e-
mail was sent to members of the nine regional associations of the Austrian organisation for heart 
and lung transplant patients (www.hlutx.at) to identify eligible participants for a Focus group. 
Guiding questions for semi-structured interviews were developed according to relevant literature 
[17], based upon a handsearch of relevant initiatives’ websites (such as the Scottish Medicine 
Consortium and its PACE process and relevant literature), and discussed among two 
researchers; a third one was consulted for an independent opinion. The four-hour face to face 
meeting was moderated by a patient support expert who also helped with gathering patients for 
the Focus group. The meeting that was held in German was recorded and transcribed upon 
approval of the participants. The anonymised transcript was analysed using framework analysis 
[17]. Extraction of patient-relevant endpoints (clustering/charting) was done by one author (from 
LBI-HTA) and checked by a second author (from LBI-HTA).  
According to the Austrian Ethics Committee, no ethical approval was needed. Patients were asked 
to sign an informed consent form. The Focus group was a pilot qualitative research done in the 
context of EUnetHTA in order to further inform appraisal of the WCD therapy. The Focus group 
questions can be found in Appendix 1.  
 
2.9 Deviations from project plan 
 Some deadlines within the timelines were postponed due to time constraints mainly 
caused by delay in finalisation of the project plan (i.e. extended scoping phase). 
 Two additional assessment elements were identified for the EFF (D0010, D0023). 
 One patient and social assessment element was deleted as there was not enough data 
found to answer the question (G0010). 
 One legal assessment element was deleted as there was not enough data found to  
answer the question (F0014). 
 Patient involvement: Analysis of the transcript was not done by two authors independently 
(one did the analysis, the other one checked it). Furthermore no patients blog, informal 
patient website or discussion forum were consulted. 
 The scope of the intervention was extended to WCD 2000, 3000, and 3100, since the  
included studies did not explicitly state which models they used. 
 Extraction table: With regard to patient characteristics, ejection fraction in % (range)±SD 
was added, duration of therapy was deleted. With regard to efficacy outcomes, first shock 
success n (%) and % of improvement in ejection fraction in mean±SD (range) were added. 
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3 DESCRIPTION AND TECHNICAL CHARACTERISTICS 
OF TECHNOLOGY (TEC) 
3.1 Research questions  
Element ID Research question 
B0001 What is the WCD and what are the comparators? 
A0020 For which indications has the WCD received CE marking? 
B0002 What is the claimed benefit of the WCD in relation to the comparators? 
B0003 What is the phase of development and implementation of the WCD and the comparators? 
B0004 Who administers the WCD and the comparators and in what context and level of care  
are they provided? 
B0008 What kind of special premises are needed to use the WCD and the comparators? 
B0009 What equipment and supplies are needed to use the WCD and the comparators? 
A0021 What is the reimbursement status of the WCD? 
 
3.2 Results 
Features of the technology and comparators 
B0001 – What is the WCD and what are the comparators? 
The WCD represents a novel therapy in primary and secondary prevention of SCA. It is a 
defibrillation technology that is worn by the patient for most of the day, except when taking a 
bath/shower when the presence of a caregiver or a family member is recommendable [4].  
The following description of the device is based upon the latest version WCD 4000. The WCD 
consists of two main components: (1) an electrode belt and garment that surrounds the patient’s 
chest, and (2) a monitor that the patient wears around the waist or from a shoulder strap. The 
electrode belt connects to the monitor and provides digitised ECG data [5]. The electrode belt 
further contains a vibration box that vibrates when a treatable arrhythmia is detected [5]. The 
garment comes in various sizes and is worn under the patient’s clothing to hold four dry, non-
adhesive sensing electrodes and three therapy pads on the electrode belt against the patient’s 
skin [5, 6]. After taking out the set of electrodes, the garment should be washed every one or 
two days [5]. The monitor weighs a total of 600 g and it contains response buttons, alarm system, 
defibrillator, and batteries that last for 24 hours and can take up to 16 hours to charge [6]. The 
patient is provided with a total of two battery packs [5]. The monitor connects to the electrode 
belt, it analyses ECG data, and communicates with the charger to provide encrypted data for 
viewing availability on LifeVest® Network [5]. For depiction, see Figure 2: The garment and the 
electrode belt [5] 
The WCD monitors the patient’s heart continuously and in case it detects a life-threatening heart 
rhythm that it can restore, such as VT or VF, it delivers an automatic treatment shock [5]. Once it 
detects such treatable arrhythmia, an alarm sequence, which is to alert the patient, begins. The pa-
tient is instructed to sit or lie down to avoid injury in the event of loss of consciousness [6]. In case 
of alarm, the conscious patient can prevent the shock by pressing two response buttons found on 
the monitor unit anytime during the treatment sequence. If, however, the patient does not respond 
or release the response buttons, the WCD continues to give alarms, vibration and two alarms  g 
to bystanders that a treatment shock is imminent [5]. Then, the electrode pads release a blue gel 
prior to delivering the treatment shock and in case a treatable arrhythmia persists after the first 
shock, up to 5 shocks may be given in a treatment sequence [5]. After receiving a WCD shock 
therapy, patients are instructed to call their doctor or seek medical attention, where evaluation of 
arrhythmias that triggered the shock and replacement of the old electrodes should be provided [6].  
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Figure 2: The garment and the electrode belt [5] 
 
The WCD can be programmed to different VT or VF zones and can be adjusted to different times 
(time from detection to defibrillation sequence activation) and shock energy (between 75 and 150J, 
biphasic) [6]. A single shock event typically takes less than one minute. Apart from defibrillation as 
such, the device continuously monitors for VTs and VFs and can transmit event recordings to an 
internet website that allows a patient’s health care professional to view the ECG and other data 
related to the patient’s use of the device.  
 
Marketed products 
Currently, there is only one WCD on the market, the LifeVest® WCD manufactured by ZOLL 
Medical Corporation (see Table 3: Features of the intervention). The LifeVest® WCD has five 
generations. The 1st generation, WCD 1, received the CE mark in 1999 and together with the 2nd 
generation, WCD 2000, it delivered shocks in the form of monophasic waveforms with a maximum 
of 300J. The 3rd generation, WCD 3000, the 4th generation, WCD 3100, and the latest 5th 
generation, WCD 4000 – CE marked in 2011, all deliver biphasic shocks with a maximum of 150J 
[5]. Only the WCD 4000 is currently offered in Europe. 
 
Standard treatments 
There are four categories of standard treatments, depending on the indication, that are being re-
placed, postponed, bridged, or optimised by the introduction of the WCD for the management of 
VA and for the prevention of SCA [7, 36]: ICD, GL directed pharmacological therapy, GL directed 
catheter (radiofrequency) ablation, and AEDs available at public places and/or used by medical 
emergency staff during resuscitation.  
 The ICD has been in use for more than three decades since its first implantation in the 
1980 and it is now an established first line treatment and prophylactic therapy for patients 
at risk of SCA due to its ability to perform defibrillation, cardioversion, and pacing [6, 37]. 
It has the capacity to correct most arrhythmias and its battery life is six to ten years. It can 
be implanted transvenously or subcutaneously [8]. 
o Transvenous ICD is implanted under the skin in the left upper chest and it comprises 
of 1) a generator that includes a computer chip with a RAM memory, software, capac-
itor, and batteries, and 2) electrode wire/s connected to the generator that pass through 
a vein to the right chambers of the heart and can consist of one to two leads [8]. 
Furthermore, when choosing the right ICD, what needs to be considered is whether 
to choose a single or dual chamber ICD, and whether to combine it with cardiac 
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resynchronisation therapy (CRT-D). A dual chamber ICD is to be considered in 
patients with significant sinus bradycardia due to sinus node disease, or the 
presence of an atrial lead that would allow an increase in beta-blocker dose [8]. 
Combining the ICD with CRT should be considered in patients with LVEF <35% and 
with broad QRS duration—particularly those with left bundle branch block (LBBB) [8].  
o Subcutaneous ICD (S-ICD) is comprised of a subcutaneous lead that runs parallel to 
the left sternal edge and along the inferior border of the heart to a generator in the axilla 
[8]. S-ICD’s target population are younger patients with no indications for bradycardia 
or anti-tachycardia pacing [8].  
 GL directed pharmacological therapy is based on the associated arrhythmia, the 
associated medical conditions that may contribute to and/or exacerbate arrhythmia, the 
risk posed by arrhythmia, and the risk – benefit aspects of the potential therapy [36]. The 
management of VAs includes discontinuation of offending pro-arrhythmic drugs and 
appropriate anti-arrhythmic therapy that includes a) anti-arrhythmic drugs, such as 
amiodarone, or beta-blockers (for the full list, please see Table 15: Antiarrhythmic drugs 
for treatment of VT/VF [1] in the Appendix 4), b) electrolytes, such as potassium or 
magnesium, or c) other drugs that improve reverse remodelling, such as angiotensin-
converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and 
mineralocorticoid receptor antagonists (MRAs) [36], or drugs that are helpful for reducing 
the frequency of coronary thrombotic occlusions in high-risk patients, such as 
anticoagulants and antiplatelet drugs [36]. 
 GL directed catheter (radiofrequency) ablation is a treatment option for patients with scar-
related heart disease presenting with VT or VF. Catheter (radiofrequency) ablation in 
ischaemic heart disease patients decreases the likelihood of subsequent ICD shocks 
and prevents recurrent episodes of VT [36]. It targets the isthmus of slow conduction 
(critical isthmus) within the VT re-entry circuit [36]. The procedure involves a series of thin 
and flexible catheters (wires) that are inserted in a blood vessel via the patient’s neck, 
groin, or arm. Guided to the heart, the catheters carry heat energy (created also by radio 
frequency medium alternating current in the range of 350–500 kHz) that destroys those 
areas of the heart where abnormal heartbeats cause arrhythmias [36].  
 AEDs, available at public places and/or used by medical emergency staff during 
resuscitation, are another treatment option for patients at risk of SCA. Most SCAs occur 
outside of the hospital setting and public access defibrillation combined with 
cardiopulmonary resuscitation has been shown to be effective particularly at places where 
trained volunteers can be readily available (e.g. casinos, airports, sports stadiums) [36]. 
Even though most SCAs occur at home, as they are infrequently witnessed, home-based 
defibrillators are scarcely helpful [36]. 
Table 3: Features of the intervention 
 
Technology 
Name Wearable cardioverter defibrillator 
Proprietary name LifeVest® wearable cardioverter defibrillator 
Manufacturer ZOLL Medical Corporation 
Names in other countries NA 
Reference codes FDA Product code: MVK 
CE Mark certificate unique ID: DRKS00005653 
Class/GMDN code 35972 – Defibrillator, Automatic 
Abbreviations: CE-Conformité Européene; FDA-Food and Drug Administration; GMDN-Global medical device nomenclature; 
ID-identification; NA-not available. 
Sources: [5] 
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A0020 – For which indications has the WCD received marketing authorisation  
or CE marking? 
LifeVest® WCD received the CE mark for its 1st generation model, WCD 1, in 1999 and for the 
latest, 5th generation WCD 4000, in 2011. The LifeVest® system is indicated for patients 18 years 
of age and older who are at risk for SCA and are not candidates for or refuse an ICD [5]. The 
device first received an FDA approval in 2001 and in 2015, it received the FDA approval also for 
children who are at risk for SCA, but are not candidates for an ICD due to certain medical 
conditions or lack of parental consent [9]. Information on the regulatory status is found in Table 
12: Regulatory status of the technology. 
 
B0002 – What is the claimed benefit of the WCD in relation to the comparators? 
LifeVest® WCD claims to offer temporary protection from SCA in high risk periods during 
diagnosis, or an experience of VT/VF, and the appropriate treatment (or optimisation of it). In 
these so called “bridging” periods, a WCD claims to a) allow for implantation of ICDs only in the 
cases where it is required (in order to prevent possible morbidity issues linked with complication 
post ICD implantation such as infections [38] and the high cost of an ICD implantation as such 
[1]), b) provide protection during drug optimisation, c) allow for recovery of the heart function and 
the improvement of the LVEF, and d) provide protection to at risk heart transplant patients. 
 
B0003 – What is the phase of development and implementation  
of the WCD and the comparators?  
The WCD received its CE mark in 1999 based upon a 1998 study of induced arrhythmias in ten 
patients [39]. Currently, it is the 5th generation of the device that is in use and this novel 
technology is trying to find its place in clinical practice. As the device can be used for multiple 
indications, risk stratification for each indication is the subject matter that needs to be 
determined. Current clinical trials are investigating the use of the device in further subgroups of 
patients at risk of SCA and an altered form of the device, hospital WCD, that is not part of this 
assessment, is being researched. Data on implementation of the device based upon 
retrospective registry studies in the US and Germany are outlined in the Table 4: Registry 
experience with WCD indications in the US and Germany below.  
Table 4: Registry experience with WCD indications in the US and Germany 
Indications US [24] in % Germany [40] in % 
ICD explants 23.4 10 
VT/VF prior to ICD implants 16.1 NA 
Genetic predisposition to SCD 0.4 18 (part of it)* 
Recent MI  
Recent MI  
12.5 (and LVEF ≤ 35%) 
3.8 (and LVEF >35%) 
39 
Post-CABG  8.9 (and LVEF ≤ 35%) 25 
Cardiomyopathy 20 (Nonischaemic cardiomyopathy and LVEF ≤ 35%) 
8.1 (Unspecified cardiomyopathy and LVEF ≤ 35%) 
18 (part of it)* 
Heart transplantation or left 
ventricular-assist devices 
NA 6 
Unknown 6.8 NA 
*  The category of “risk stratification” that makes up 18% of patients includes assumed myocarditis/dilated cardiomyopathy, 
aborted SCA, and inherited channelopathies (LQTS, Brugada syndrome). 
Abbreviations: ICD-Implantable Cardioverter Defibrillator; LVEF-Left Ventricular Ejection Fraction; MI-Myocardial Infarction; 
CABG-Coronary artery bypass grafting; NA-not available; US-United States. 
Sources: [24] [40] 
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ICDs are part of the established clinical practice and current developments are concerned with a) 
the use of CRT-D alongside ICD implantation, b) the implantation of single, or dual chamber ICDs, 
and c) the implantation of transvenous or subcutaneous ICDs [8]. The compatibility between ICDs 
and Magnetic Resonance Imagining is currently being researched as well [41]. 
Pharmacological therapy has shown limited success in preventing SCAs [37]. Anti-arrhythmic drug 
therapy has shown little success with sodium channel blockers, calcium antagonists, blockers of 
potassium channels, or amiodarone [37]. For patients post MI and patients with heart failure, 
anticoagulants, ACE inhibitors, statins, and aldosterone antagonists have been shown to reduce 
the incidence of SCD [37]. Currently, studies are under way that compare anti-arrhythmic drug 
therapy with catheter (radiofrequency) ablation and the question whether the primary ablation of 
well-tolerated sustained monomorphic VT in patients with an LVEF > 40% without a backup ICD 
is beneficial needs further study [36]. 
The phase of development of AEDs revolves around the simplicity of AED utilisation by lay 
persons, around comparisons between biphasic or monophasic waveforms, and around 
mechanisms of operation when used alongside with cardiopulmonary resuscitation [42]. 
 
B0004 – Who administers the WCD and the comparators and in what context  
and level of care are they provided? 
B0008 – What kind of special premises are needed to use the WCD and the comparators? 
B0009 – What equipment and supplies are needed to use the WCD and the comparators? 
Strictly speaking, the WCD system does not require any bystander or healthcare provider 
interaction to deliver the required treatment. However, a cardiologist needs to decide on the 
time from detection to defibrillation sequence activation and the required shock energy (between 75 
and 150J, biphasic) [6]. Also, for the device to fulfil its “bridging” purpose, the data gathered by 
the device need to be analysed by the cardiologist, so that the appropriate treatment method is 
selected. The WCD’s primary target is out-of-hospital patients who, however, should call their 
doctor or seek other immediate medical evaluation after receiving a shock [6]. No additional 
equipment, premises, or personnel of the health care provider or system are necessary for the 
use of the WCD [5]. 
Maintenance costs and investments necessary to support the use of the WCD are, for the time 
being, defrayed by the manufacture ZOLL Medical Corporation. The LifeVest® WCD system is a 
service that includes training and 24/7 technical assistance and support by ZOLL Medical 
Corporation trained representatives. If component replacement is needed, it is typically done 
within 24 hours and once a patient completes use, the registered LifeVest® is returned for cleaning 
and testing of the device with reconditioning or repair completed when required. Devices must 
pass an inspection and testing process in order to be sent to another patient. Devices that do not 
pass this inspection process are fully serviced or removed from patient’s use if they cannot be 
repaired [5]. 
Implantation of the ICD, as well as catheter (radiofrequency) ablation, are administered in the 
hospital setting. Catheter (radiofrequency) ablation is performed under local anaesthesia and the 
ICD implantation can be performed both under general anaesthesia as well as local anaesthesia 
with sedation [43, 44]. The premises, the operation team, and the supplies are similar; the 
difference between catheter (radiofrequency) ablation and implantation of the ICD is in the 
intervention, where ablation is a one-off treatment while the ICD is an implanted device. If 
successful, catheter (radiofrequency) ablation requires less follow-up visits compared to post-ICD 
monitoring by the cardiologist [43].  
Pharmacological therapy is prescribed by cardiologists and taken in the out-of-hospital setting. AEDs 
are administered in emergency units by the emergency unit personnel, by trained volunteers at 
public places, caregiver staff in nursing homes, or family members in the home settings.  
 
  
WCD therapy for prevention of SCA 
Version 1.4, November 2016 EUnetHTA JA3 WP4  26 
A0021 – What is the reimbursement status of the WCD? 
The WCD is currently approved for use in Europe, United States, Australia, Israel, Japan and Sin-
gapore, and has regulatory approval, but is not yet launched in Canada and China. The WCD is 
fully reimbursed for particular indications in France, Luxemburg, and Switzerland (see Table 13: 
Summary of reimbursement recommendations in European countries for the technology in 
Appendix 2). In Germany, Sickness Funds make individual decisions regarding reimbursement 
because the LifeVest® is included on the Hilfsmittel list for medical supplies [45] – see Table 14: 
Summary of recommendations in European countries for the technology in the indication under 
assessment. In the UK, hospitals will rent the LifeVest® directly from the manufacturer if they 
choose to use it [5]. No monthly reimbursement estimate from the manufacturer ZOLL Medical 
Corporation was provided. 
 
3.3 Discussion 
Some device characteristics such as the garment size, limited device functions, noise disruptions, 
and differences between shock waveforms need to be reflected upon and further discussed.  
Especially in the context of making comparisons between a WCD and an ICD, it is important to 
highlight the issues related to the garment size. The device must be fitted to each patient and some 
patients may not have a good fit due to body habitus [23]. The maximum chest circumference for 
patients wearing the WCD is 144cm, which means that morbidly obese patients are left 
unprotected [23]. In this report, the use of the WCD in children under 18 years of age is analysed 
even though it is not approved in Europe, but only in the USA. In the absence of clinical trials that 
would meet the selection criteria, no data on effectiveness and safety is reported, yet the garment 
size remains to be an issue. The minimum weight for use of the WCD is 18.6kg and minimum 
chest circumference 66cm [4]. Not only size limitations, but also issues with fitting of the garment 
seem to be responsible for providing low protection to children under 18 years [4]. 
To date, the WCD has no pacing capabilities for backup bradycardia pacing or for anti-tachycardia 
overdrive pacing [4, 6], which leaves those groups of patients for whom ICD is a comparator 
particularly unprotected, as these functions are offered in the new generations of ICDs [43]. In 
these circumstances then, the WCD finds itself in an ambiguous situation where on the one 
hand, it claims to offer protection to patients at risk of SCA, yet on the other hand, it offers 
protection only against SCAs induced by VT or VF [4], compared to an ICD that can provide 
both bradycardia pacing as well as anti-tachycardia overdrive pacing. Also, an inappropriate 
WCD shock can potentially induce VF as it may not be synchronised correctly [25]. 
Not only that the WCD does not provide protection in the form of pacing, it has also shown a 
possible incompatibility with unipolar pacing technologies [25]. A case occurred where a patient 
using a WCD developed a polymorphic VT, which was correctly detected by the WCD and the 
treatment protocol was initiated. However, inconsistencies in the analysed arrhythmia waveform 
due to the presence of the unipolar ventricular pacemaker artefacts led to termination of the 
treatment algorithm, which lead to patient’s death [46]. 
The 1st and 2nd generation of WCDs delivered shocks in the form of monophasic waveforms with a 
maximum of 300J, while typically programmed to begin a treatment sequence with an energy level 
of 200J [47]. The 3rd, 4th, and the latest 5th generation deliver biphasic shocks with a maximum of 
150J based upon a prospective, randomised study done in an electrophysiological laboratory 
setting with 30 patients that concluded that first shock defibrillation efficacy rate was 97% 
regardless of the waveform used [26]. Using lower-energy waveforms provides technical 
advantages (i.e. smaller and lighter devices as well as longer battery longevity). Data on the 
suitability of the different waveforms for either VT or VF was not found. In the latest generation, 
there are several settings that can be changed in the monitor of the WCD e.g. the pulse energy 
(75-150J), whereas the default setting is 150J for 5 shocks [48]. An observational study 
suggested programming the WCD to deliver maximum shock energy (150J), beginning with the 
first shock in ambulatory patients, but no dose-dependent differences were evaluated [47]. 
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4 HEALTH PROBLEM AND CURRENT USE OF THE TECHNOLOGY (CUR) 
4.1 Research questions 
Element ID Research question 
A0002 What is the disease or health condition in the scope of this assessment? 
A0003 What are the known risk factors for SCA? 
A0004 What is the natural course of VT/VF and SCA? 
A0005 What are the symptoms and the burden of SCA? 
A0006 What are the consequences of SCA for the society?  
A0024 How is the risk of SCA currently diagnosed according to published guidelines  
and in practice? 
A0025 How is SCA currently prevented and managed according to published  
guidelines and in practice? 
A0007 What is the target population in this assessment? 
A0023 How many people belong to the target population? 
A0011 How much are the WCDs utilised? 
 
4.2 Results 
Overview of the disease or health condition 
A0002 – What is the disease or health condition in the scope of this assessment? 
The LifeVest® claims to reduce the risk of SCA, the health condition in the scope of this assess-
ment. VF and VT, with a subset of Torsades de Pointes (TdP), are responsible for the majority of 
SCAs. Both of these rapid heart rhythms arise in the heart’s lower (pumping) chambers, the 
ventricles. While VT is a fast, but regular heart rhythm, VF is irregular and unsynchronised. When 
fibrillating, the heart stops pumping blood, which leads to SCA. Further causes of SCA are slow 
heart rate (bradycardia), no cardiac electrical activity (asystole), or electromechanical dissociation 
post-acute MI [10, 36].  
 
A0003 – What are the known risk factors for SCA? 
Overall, the risk factors associated with SCA differ in young and older individuals. There is a 
predominance of myocarditis and substance abuse, channelopathies and cardiomyopathies in 
young patients, and chronic degenerative diseases in older patients (CAD, valvular heart 
diseases, and heart failure) [36]. In the older individuals, multiple chronic cardiovascular 
conditions contribute to the risk of SCA and hence it is difficult to determine which contributed 
most, while in the younger individuals, inherited channelopathies or drug-induced arrhythmias 
that are devoid of structural abnormalities may make the diagnosis of SCA elusive [36]. 
Dysfunction of the left ventricle is a significant determinant of the risk of SCA, but family history, 
diabetes mellitus, obesity, and heart rate profile during exercise make the determinants diverse 
and multifactorial [49]. Lifestyle is very important in prevention of SCA (e.g. no smoking, sports, 
healthy diet) [37]. 
Particular risk factors for VT/VF caused SCA are determined by respective indications. Patients 
with the following indications are at most risk according to the AHA and the European Society of 
Cardiology (ESC) [7, 36]: 
 Who are awaiting ICD implantation after an explantation and in whom immediate 
reimplantation is not possible due to temporary contraindications or waiting time for the 
ICD implantation. 
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 Who are indicated for an ICD, but refuse it due to personal or other reasons. 
 Who need optimisation of pharmacological therapy to resolve the left ventricular dysfunction 
such as ischaemic heart disease patients with envisaged or recent revascularization (90-
day waiting period post revascularization with either CABG or PCI); newly diagnosed NICM 
patients starting (GL directed) medical therapy; secondary cardiomyopathy patients (tachy-
cardia mediated, thyroid mediated, etc.) with induced arrhythmias (secondary to hypother-
mia, electrolyte imbalance, iatrogenic prolongation of the QT interval, etc.) in which the 
underlying cause is potentially treatable; or patients with certain forms of structural heart 
disease associated with the risk of malignant arrhythmias, and in those with significantly 
impaired left ventricular systolic function. 
 Who are at risk of SCA and in the process of diagnosis. 
 Who are post MI and have their LVEF ≤ 35% and are awaiting therapy. 
 Who are awaiting a heart transplant. 
 
A0004 – What is the natural course of VT/VF and SCA? 
A0005 – What are the symptoms and the burden of SCA? 
The natural course of an SCA is death and survival with good neurological function that occurs in 
a small minority of patients [5]. SCAs occur without warning, and because patients tend to lose 
consciousness within seconds they cannot call for help. In the absence of timely defibrillation 
delivered within minutes, the SCA is typically life-threatening and with each passing minute, a 
patient’s chances of survival drop by 10% [5]. Around one third of patients with significant left 
ventricular dysfunction recover and move to a lower SCA risk category, while those that do not, 
are for the most part indicated for a permanent ICD implantation. Those patients in whom risk is 
not related to left ventricular dysfunction generally have a temporary contraindication for ICD 
placement that resolves over time [5]. Symptoms that indicate further evaluation for the risk of SCA 
are palpitations (or sensation of sudden rapid heartbeats), pre-syncope, and syncope [36]. The 
burden of disease for the patient is death, or the consequences that follow a delayed 
intervention, mainly a permanent neurological deficit. 
 
Effects of the disease or health condition 
A0006 – What are the consequences of SCA for the society? 
Approximately 25% of all 17 million deaths worldwide related to cardiovascular disease are caused 
by SCA each year [1, 5]. In Europe, there are about 350 000 out of hospital SCAs per year [12] 
and in the US, it is estimated that 326 000 people experience out-of-hospital SCA each year, while 
majority of these SCAs occur at home with half of the cases unwitnessed (39). In Austria, 
approximately 15 000 people are affected by SCD per year. One third of SCDs happen 
unexpectedly outside of hospital (i.e. 5 000). Of these 5 000 SCDs, two thirds occur at home and 
the remainder of SCDs occur in the office or in public [13]. 
 
Current clinical management of the disease or health condition 
A0024 – How is the risk of SCA currently diagnosed according  
to published guidelines and in practice? 
For non-invasive as well as invasive methods for the evaluation of patients with suspected or known 
VAs – see Table 16: Non-invasive and invasive evaluation methods [1] in the Appendix 4. 
Because of the limited ability to prevent SCAs, risk predictors remain the only reliable 
indicators. However, as low LVEF is one of the key indicators, it fails to grasp 50% of SCA victims 
whose LV function is preserved [50]. The diagnostic work-up for patients at risk of SCA is reported 
in Figure 3: Diagnostic work-up [1] in Appendix 4. 
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A0025 – How is SCA currently prevented and managed according  
to published guidelines and in practice? 
Nationwide screening for the risk of SCA is rare as only Italy and Japan have implemented ECG 
screening systems that may identify asymptomatic patients with inherited arrhythmogenic 
disorders [36]. There is a consensus among Europe and the US that there is a need for SCA 
screening in competitive athletes (as endorsed by the International Olympic Committee), even 
though a recent study in Israel reported no change in incidence rates of SCA in competitive 
athletes following implementation of screening programs [36]. 
The screening of families of SCA victims is of importance. The diagnosis of an inherited arrhyth-
mogenic disorder is established in up to 50% of the families with the sudden arrhythmic death 
syndrome victim, especially channelopathies, where currently only 40% of family members are 
screened [36]. 
For most patients at risk of SCA, implantation of an ICD is the solution of choice. Alternative 
solution is the use of pharmacological therapy, catheter (radiofrequency) ablation, and the use of 
AEDs, as outlined above. However, there remain to be specific high risk patient groups whose 
protection is an unmet need, such as post-MI patients, who are recommended not to be implanted 
with the ICD <40 days post-MI with no revascularization, or patients requiring timely defibrillation 
by AEDs – for bystander use of the AED is not an effective method of protection for high risk 
patients [51] and relying on emergency medical service response also results in poor outcomes 
[52].  
The WCD is recommended based upon a low level of evidence by the ESC for adult patients with 
poor LV systolic function who are at risk of sudden arrhythmic death for a limited period, but are 
not candidates for an ICD (e.g. bridge to transplant, bridge to transvenous implant, peripartum 
cardiomyopathy (PPCM), active myocarditis, and arrhythmias in the early post-MI phase) [1, 29]. 
The AHA states along the same lines that WCDs can serve as a temporary means of aborting 
arrhythmic death in patients with transient risk of SCD or those with indications for ICD 
implantation who have a transient barrier to permanent device implantation [7]. For more data on 
GL directed WCD use, see Table 5: Overview of guidelines in Appendix 1. 
 
Target population 
A0007 – What is the target population of this assessment? 
A0023 – How many people belong to the target population? 
A0011 – How much are the technologies utilised?  
As CE marked, the target population of this assessment are patients 18 years of age and older who 
are at risk for SCA and are not candidates for or refuse an ICD.  
Worldwide, there are 4.25 million deaths caused by SCA each year [5], however, the exact target 
population of this intervention is difficult to estimate. One approach would be to estimate it based 
on the ICD usage. In 2014 in Austria, 1045 patients received an ICD (men: 842, women: 203) [53]. 
However, this approach is inaccurate because some patients who are indicated for an ICD may 
not receive one, while some patients who receive an ICD may have a condition that would have 
improved without one [54]. Contributing to the estimate are 57 patients that had their hearts 
transplanted in Austria in 2007 [55], whereas this number in Germany in 2015 was 286 patients 
[56].  
The expected annual prescription of WCD is 160 prescriptions per year in Austria, when assuming 
the same prescribing practice as in the US. 
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4.3 Discussion 
Some aspects of the current and future use of the WCD such as the indication, off-label use, risk 
stratification, WCD’s role as a prevention or treatment, and the unclarity in care pathways need to 
be further discussed.  
Due to the fact that WCD is CE marked very broadly, for patients 18 years of age and older who 
are at risk for SCA and are not candidates for or refuse an ICD, the device indications and the 
patients that benefit most from the device are not clearly defined [5]. The list of indications 
considered in this report is the result of consulting international GLs, clinical/external experts, 
and project partners. This broad CE mark definition that does not specify concrete indications 
leaves room for broad use of the WCD. 
Connected to the issue of CE mark is the issue of risk stratification. As the WCD claims to provide 
protection in the “bridging periods” only against specific arrhythmias (VTs/VFs) and the prevalence 
of these types of arrhythmias is not reported in the studies, it is unclear which patients can benefit 
the most from the WCD. In this way, the WCD serves as a tangible insurance that, as indicated in 
the two studies with larger cohorts of patients included in this assessment [18, 22], delivered 
appropriate shocks to less than 2% of the patients (described in further detail in the EFF 
discussion) [23]. Hence, due to the potential for the device overuse driven by the inevitable fear 
behind the risk of SCA, there is a particular need for setting a threshold of risk for particular 
patient groups. This is also suggested by Singh for NICM patients, where none of the 254 
patients in the retrospective study independent from manufacturer sponsorship actually received 
an appropriate WCD shock, which casts doubts on the actual risk of SCAs in NICM patients [57]. 
Therefore, there is a need for more data in order to analyse the WCD’s place in clinical practice 
so that it is not prescribed for patients that do not need it out of fear [58]. In particular, more data 
is needed for specific risk stratification of high risk patients whose data is available, yet reported 
as part of larger subgroups. That skews the results and presents the WCD as the treatment of 
choice for the whole subgroup, even though it is most needed for the high risk patient groups as it 
is the case in [22], where e.g. previous SCA and syncope patients at highest risk fall under the 
general subgroup of NICM. In order to establish risk factors for SCA, it is necessary to use the 
manufacturer ZOLL Medical Corporation data from the company’s database. 
Following the AHA, the WCD is analysed as a treatment option for VT and VF [7]. However, 
because VT and VF lead to SCA, the risk of which is the health condition in the scope of this 
assessment, the WCD is also understood as a primary as well as secondary preventative 
measure; primary in patients post-MI or post-explantation of an ICD when immediate 
reimplantation is not possible, and secondary in patients with a history of SCA or sustained VT 
and VF, in whom ICD is ineffective. The well-defined role of the WCD in treatment and prevention 
needs to be clarified. 
There is a lack of published data on the management of specific patients in whom the first line 
therapy is not successful. It is unclear what the care pathway is for patients who, for instance, 
have an ICD removed due to an infection or other comorbidities that contraindicate reimplantation. 
The ESC suggests that the subcutaneous ICD may be considered as a useful alternative to the 
transvenous ICD system in such circumstances [1], yet the AHA outlines that the subcutaneous 
ICD shares many of the same hazards as transvenous ICDs, including lead dislodgement, skin 
erosion, and infection, along with the incidence of inappropriate shocks [7]. Same unclarity 
applies to the care pathways for patients who are awaiting optimisation of pharmacological 
therapy, or in whom catheter (radiofrequency) ablation was not successful. In such situations, 
patients seem to be dependent on the emergency services and the use of AEDs. In these 
circumstances as well as when the “watch and wait” strategy can be applied, the WCD might be 
potentially useful, but more comparative data for risk stratified subgroups is needed to establish 
the WCD’s effectiveness. 
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5 CLINICAL EFFECTIVENESS (EFF) 
5.1 Research questions 
Element ID Research question 
D0001 What is the expected beneficial effect of the WCD on mortality  
(disease-specific and all-cause)? 
D0005 How does the WCD affect symptoms and findings (severity, frequency) of VT/VF? 
D0006 How does the WCD affect progression (or recurrence) of VT/VF? 
D0011 What is the effect of the WCD on patients’ body functions? 
D0016 How does the use of WCD affect activities of daily living? 
D0012 What is the effect of the WCD on generic health-related quality of life? 
D0013 What is the effect of the WCD on disease-specific quality of life? 
D0017 Were patients satisfied with the WCD? 
D0010 How does WCD modify the need for hospitalisation?  
D0023 How does WCD modify the need for other technologies and use of resources?  
 
5.2 Results 
Included studies 
No study fulfilled the study inclusion criteria for assessing clinical effectiveness of the WCD. RCTs 
and non-randomised CTs were considered for inclusion, but could not be identified through the 
systematic literature search (see Figure 1: Flow chart).  
Non-randomised CTs were listed in the inclusion criteria in the attempt of providing the ‘best guess’, 
rather than no answer at all, for the relatively new technology of WCD regardless of its not-very-
large effect, even though an RCT would be possible and ideal for assessing clinical effectiveness [3]. 
Study characteristics (see results in SAF) 
Patient characteristics (see results in SAF) 
 
Mortality 
D0001 – What is the expected beneficial effect of the WCD on mortality  
(disease-specific and all-cause)? 
No evidence was found to answer the research question. 
 
Morbidity 
D0005 – How does the WCD affect symptoms and findings (severity, frequency) of VT/VF? 
No evidence was found to answer the research question. 
 
D0006 – How does the WCD affect progression (or recurrence) of VT/VF?  
No evidence was found to answer the research question. 
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D0011 – What is the effect of the WCD on patients’ body functions? 
No evidence was found to answer the research question. 
 
D0016 – How does the use of WCD affect activities of daily living? 
No evidence was found to answer the research question. 
 
Health-related quality of life 
D0012 – What is the effect of the WCD on generic health-related quality of life? 
No evidence was found to answer the research question. 
 
D0013 – What is the effect of the WCD on disease-specific quality of life? 
No evidence was found to answer the research question. 
 
Satisfaction 
D0017 – Were patients satisfied with the technology? 
No evidence was found to answer the research question. 
 
Change-in-management  
D0010 – How does WCD modify the need for hospitalisation? 
No evidence was found to answer the research question. 
 
Resource utilisation 
D0023 – How does WCD modify the need for other technologies and use of resources? 
No evidence was found to answer the research question. 
 
5.3 Discussion 
Although the WCD was first approved in 1999 in Europe and in 2001 in the US, valid data on clinical 
effectiveness and safety of the device are scarce. The WEARIT/BIROAD study (including 289 
patients), completed in 2001, in which pre-specified safety and effectiveness GLs had been met1 
[18], was crucial in getting the FDA approval for the WCD. The current assessment of effectiveness 
was restricted to prospective CTs, of which none was identified. Due to the lack of RCTs 
comparing the WCD with the ICD, GL directed pharmacological therapy, GL directed catheter 
(radiofrequency) ablation, and AEDs (comparator might vary depending on indication), strong 
evidence on patient benefit is missing. However, there exist many retrospective registry studies (> 
15), majority of which are based upon ZOLL Medical Corporation datasets. 
                                                     
1
 The study was designed to test the hypothesis that successful resuscitations would occur in at least 25% of events.  
The power had to be at least 50% if the true successful resuscitation rate was 43%. 
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Though no evidence from comparative trials is available, the data gathered in non-comparative 
studies [18-22] – also extracted for information on safety – are presented here. The following 
effectiveness outcomes were compiled: mortality during the course of the study (all-cause and 
disease specific i.e. prevention of SCA), incidence of VT/VF, appropriate shocks, withheld shocks 
(due to patients using the response button to delay therapy), first shock success, patient 
compliance (WCD wear-time, WCD daily use), avoidance of ICD implantation, and improvement 
in LVEF. 
All-cause mortality ranged from 0 to 4.2% across the five studies. Due to the small sample size in 
three studies [19-21], the lack of comparator, and the variety of enrolled patient groups (with regard 
to co-morbidities, disease progression, diagnosis) in all five included studies (for the assessment 
of safety), no valid statement can be made whether mortality increased or decreased. Same applies 
for disease specific mortality which ranged from 0 to 2.1% in the five studies. Furthermore, only one 
study reported on resuscitated cardiac arrest: two patients experienced unsuccessful shocks due 
to incorrect placement of therapy electrodes, but one of the events was nonfatal since the patient 
received a successful external defibrillation [18]. Incidence of VT/VF ranged from 2.1% [22], to 8% 
[20], to 43% [19], however, each patient could have had more than one VT/VF event. Appropriate 
shocks ranged from 1.1 to 8% [18, 20, 22] up to 43% [19], whereas one registry study did not 
report on this outcome [21]. One registry study reported on withheld shocks (1.1%) [22], whereas 
it was not reported if the use of the response button was indicated i.e. used correctly. The first shock 
success rate was 100% in three studies [19, 20, 22], whereas it was not mentioned in the 
remaining two studies [18, 21]. Compliance was measured as the WCD wear-time and WCD daily 
use, no subjective patient data was collected. The WCD wear-time was indicated as mean or 
median days ranging from 33 to 94. Four of five studies reported the WCD daily use of 21.8 to 
23.1 hours (mean/median) [19-22]. Avoidance of ICD implantation was shown in one study 
(40%) [22], unclear in three studies [19-21], and not reported on in one study [18]. Improvement in 
the LVEF was indicated in three studies as mean or median (5-22.5%) [19-21] and left unreported 
in two studies [18, 22]. For the outcome satisfaction with the technology, no standardised 
measure (like a standardised questionnaire etc.) was applied in any of the five studies and could 
therefore not be compiled. No information on hospitalisation or HRQoL was reported. 
It would be important to have the information on long-term mortality (> 1 year) from prospective 
studies. One study stated that the patients who died had an LVEF improvement at the time of the 
WCD end of use [21], further patients died after WCD use due to unknown causes. This could 
suggest that even though patients´ LVEF improved, it does not imply that the patients no longer 
need an ICD. So the measure of improvement of LVEF could be questioned, since first of all, the 
improvement might not last life-long and second of all, other indications might emerge that 
could make the ICD an option. Patients’ follow-up and the identification of cause of death would 
be important. The value of the LVEF represented inclusion criteria for the ICD trials in the past, 
which might be one of the reasons why it is used in the WCD trials as well. LVEF was measured 
before and after the WCD use in all four studies – except in one where it was only measured at 
the beginning [18]. The discussions regarding the use of LVEF as a criterion for the ICD 
implantation and as a predictive value for arrhythmic events are ongoing [59]. This issue also 
questions the “watch and wait strategy” in which patients are monitored whether their disease 
status improves.  
Patients suffering from a heart disease often have comorbid diseases like diabetes, hypertension 
etc., which were not reported in two out of five studies [19, 20], whereas these studies mentioned 
that patients entered the study at a similar point in the disease. Only one out of five included 
studies grouped patients according to disease aetiology: ischaemic CM, NICM, 
congenital/inherited heart disease [22]. The remaining studies did not distinguish between 
subgroups. 
Furthermore, no information on historic controls on SCA in different patient groups was provided 
in any of the five studies in order to compare how many SCAs could be avoided. The WCD was 
shown to have very little impact in the treatment of SCA, maximum of 2% of patients, who wore the 
LifeVest® received appropriate shocks in almost any cohort (see discussion of CUR). There are 
ongoing efforts to find a calculation method in order to transfer “time to event rates” into a useful 
standard (e.g. risk per month). 
Only one study out of five clearly stated the avoidance of ICD implantation (due to improved 
cardiac function) in patients who have been indicated for an ICD before the WCD use [22]. The 
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others stated ICD avoidance, but it is not clear whether the patients have been indicated for an 
ICD at the start of the WCD use. Furthermore in one study, refusal of an ICD was added to the 
ICD avoidance group [20], which should only include patients whose health condition improved 
and therefore did not need the ICD anymore. Two studies showed that there is no benefit of an 
ICD implantation within 40 days after MI [60, 61]. In 2016, an RCT demonstrated that prophylactic 
ICD implantation in patients with symptomatic systolic heart failure not caused by CAD was not 
associated with a significant reduction in long-term mortality [62]. The challenge is to target ICDs 
to the patients who will most likely benefit from them [63]. 
The existing registry studies are lacking some important information such as device model used, 
settings of the monitor, how often the response button was used, number of false alarms, possible 
device-device interactions, information whether an ICD was indicated at the beginning of the WCD 
use and possibly could be avoided after WCD use, and information on disease status (how far 
advanced the disease is) at baseline. Information on patient indication and outcome is crucial in 
order to narrow down and further specify the indications for the WCD use. Data on HRQoL and 
satisfaction should be collected by using standardised methods. 
These studies did not provide valid data on clinical effectiveness; therefore no evaluation could be 
performed. RCTs and non-randomised CTs should be pursued in order to provide a strong 
evidence base. Two RCTs, which are expected to yield robust clinical data, are already ongoing 
(see Table 8: List of ongoing studies with WCD in Appendix 1). Both RCTs use conventional 
treatment as the comparator. One study aims to be completed in December 2017 (2300 patients 
with ventricular dysfunction immediately following MI) and the other one in October 2019 (2600 
patients with end stage renal disease beginning haemodialysis). Prospective studies with long-
term mortality measures including well defined disease groups are necessary in order to 
determine the patient groups that would benefit most from the intervention. 
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6 SAFETY (SAF) 
6.1 Research questions 
Element ID Research question 
C0008 How safe is the WCD in relation to the comparator(s)? 
C0002 Are there harms related to dosage or frequency of applying the medical  
device-WCD? 
C0004 How does the frequency or severity of harms change over time or in  
different settings? 
C0005 What are the susceptible patient groups that are more likely to be harmed 
through the use of the WCD? 
C0007 Are the WCD and comparator(s) associated with user-dependent harms? 
B0010 What kind of data/records and/or registry is needed to monitor the use of 
the WCD and the comparator(s)? 
 
6.2 Results 
Included studies 
The study inclusion criteria for assessing safety differed from the one for assessing clinical 
effectiveness. In addition to RCTs and non-randomised CTs, prospective studies without a control 
group (interventional single arm studies, case series, and registry studies) were considered for 
the assessment of safety. The systematic literature search (see Figure 1: Flow chart) identified 
one prospective interventional single arm study [18], two prospective case series [19, 20] and two 
prospective registry studies [21, 22], which matched our inclusion criteria. Study characteristics 
and results of included studies are shown in Table 2. Main characteristics of studies included and 
in Table 7: Characteristics of included studies in Appendix 1. 
Study characteristics 
The prospective interventional single arm study included 289 patients (52 women and 237 men). 
Overall, 36 patients were reported on in the prospective case series, of which 14 were women and 
22 were men. The registry studies included 2089 patients, of which 623 were women and 1466  
were men. Four of five studies were sponsored by ZOLL Medical Corporation, whereas funding was 
not stated for the fifth study [20]. Countries of recruitment were United States [21, 22] and 
Germany [19, 20], or both [18]. Clinical follow up time ranged from 2.9 to 10.4 months 
(mean/median) [19-22], whereas it was unclear for one study [18]. The 12 month follow up is 
currently ongoing for one study [22]. Loss to follow up ranged from 0 to 23.5% with no information 
provided in two of the studies [20, 22]. Model versions of the technology (generations of 
LifeVest®) were not reported in any of the studies. However, one study reported that they used 
commercially available market released WCD devices [22]. The three multi-centre studies 
included 289, 89, 2000 patients respectively [18, 21, 22], and the single-centre studies 12 and 24 
patients respectively [19, 20].  
Patient characteristics 
The age range of patients varied from 18-75 [18] to 37-83 years [21], whereas no age range was 
reported in the remaining studies. All studies indicated mean or median ages for their patients be-
tween 34 and 69 years, whereas the statistical measure was not clear in one study (i.e. whether it 
was median or mean) [18]. The mean or median LVEF at baseline was stated between 23 and 
30%, whereas the statistical measure was again not clear in one study (i.e. whether it was median 
or mean) [18].  
Patient inclusion criteria showed some heterogeneity in terms of the LVEF (< 30% [18], ≤ 40% 
[21], other studies left unreported) and form/nature of heart disease (newly diagnosed PPCM [19], 
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early post-MI phase [20], and a combination of several heart disease groups [18, 21, 22]. However, 
all patients had a high risk of SCA.  
Only two studies stated patient exclusion criteria, which mainly referred to having an active ICD or 
being unable to use the WCD due to impairment [18, 21]. Only three out of five studies [18, 19, 
21] indicated previous treatments.  
Patient safety 
C0008 – How safe is the WCD in relation to the comparator(s)?  
No evidence was found to answer the research question with regard to comparison of the WCD 
with comparators, since the included studies did not have a control group.  
The following AEs were reported: Skin rash and itching, false alarms, palpitations, light-headed-
ness, and fainting, and discontinuation due to comfort and lifestyle issues. 
One study indicated skin rash and itching in 6% of patients [18], the other studies did not report on 
this AE. False alarms were reported in one study with 14% of patients having experienced 
numerous false alarms [19], the remaining four studies did not provide any information on this AE. 
Only one study reported on palpitations, light-headedness, and fainting in 9% of patients [21], the 
other four studies did not report on this AE. Two studies indicated discontinuation of the WCD 
use due to comfort and lifestyle issues, namely in 22% of patients [18] and in 16% of patients [21]. 
None of the studies reported on unexpected AEs. 
SAEs that occurred were inappropriate shocks and unsuccessful shocks. Inappropriate WCD ther-
apy was only defined in one study, in which it was classified as non-VT/VF episodes detected and 
treated by a WCD shock [22].Two studies indicated that 2% [18] and 0.5% [22] of patients 
respectively experienced inappropriate shocks, whereas the remaining three studies reported 
no inappropriate shocks. Unsuccessful shocks were reported in four out of five studies. One study 
indicated that 0.7% of patients [18] experienced unsuccessful shocks due to incorrect 
placement of the therapy electrodes. Three studies reported no unsuccessful shocks [19, 20, 22] 
and one study did not report on this outcome. 
All five studies reported on the outcome frequency of SAEs leading to death, where death occurred 
in one study (0.3%) [18]. 
 
C0002 – Are there harms related to dosage or frequency  
of applying the medical device-WCD? 
The study reporting about skin rash and/or itching, which was indicated as the major objective 
complaint with the use of the WCD, did not mention any time-dependent issues, whether it would 
get better or worse with increased use [18] – same with occurrence of palpitations, light-
headedness, and fainting [21]. 
 
C0004 – How does the frequency or severity of harms change over time  
or in different settings? 
There are several differences in the device generations. The main difference is the change from 
monophasic waveform to bi-phasic waveform (from the 3rd generation). However, the included stud-
ies did not state the device generations used and therefore no statement can be made. 
There is no evidence that harms increase or decrease in different organizational settings. 
 
C0005 – What are the susceptible patient groups that are more likely  
to be harmed through the use of the WCD? 
It was shown that patients with ischaemic and congenital/inherited heart disease had significantly 
higher probabilities of sustained VT/VF than those with NICM. Furthermore, compliance was inde-
pendent of disease aetiology (ICM, NICM, inherited/congenital heart disease) [22]. Patients who 
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have a more advanced disease status (since they might have other indications or comorbidities as 
well) might be at a higher risk to be harmed from the use of the WCD. Same applies for non-
compliant patients who might be at higher risk for unsuccessful shocks (e.g. when incorrectly 
placing therapy electrodes), or for inappropriate shocks (e.g. when incorrectly using response 
button), or for skin rash/itching when incorrectly washing the garment. Women could also be more 
likely to be harmed because of their body shape (e.g. due to fitting problems of the WCD). 
C0007 – Are the WCD and comparator(s) associated with user-dependent harms?  
Patients themselves might cause harms: One study reported unsuccessful shocks in 0.7% of 
patients due to incorrect placement of therapy electrodes [18]. Furthermore, the WCD needs to be 
worn all day and night, except when taking a bath/shower. Therefore, patient compliance is of the 
utmost importance. The WCD daily use was reported in mean and medians in four out of five 
studies, whereas it varied between 21.8 and 23.1 hours [19-22]. User information and training is 
important. 
Activation of the response button could lead to user dependent harms, since patients might push 
the button when not indicated and avert a possible life-saving treatment. Results of the Focus 
group showed that patients do not want to have the responsibility of making this decision. Only 
one out of five studies described the number of withheld shocks (1.1%) [22]. Inappropriate 
bystander intervention could pose an additional risk. 
Professionals might cause harms because of their responsibility of setting up the monitor and choos-
ing the settings (default settings can be used as well). Settings that may be modified in the monitor 
of the WCD are VT response time (60-180 seconds, default: 60 seconds), VF response time (25-
55 seconds, default: 25 seconds), VT rate threshold (120-250 beats per minute, default: 150 beats 
per minute), and VF rate threshold (120-250 beats per minute, default: 200 beats per minute) [48]. 
 
B0010 – What kind of data/records and/or registry is needed  
to monitor the use of the WCD and the comparator(s)? 
The existing registry studies are lacking some important information such as device model used, 
settings of the monitor, how often the response button was used, number of false alarms, possible 
device-device interactions, information whether an ICD was indicated at the beginning of WCD 
use and possibly be avoided after WCD use, and information on the disease status (how far 
advanced the disease is) at baseline. Information on patient indications and outcomes is crucial 
in order to narrow down and further specify the indications for WCD use. Data on HRQoL and 
satisfaction should be collected using standardised methods. 
 
6.3 Discussion 
For the evaluation of safety data, one prospective interventional single arm study [18], two 
prospective case series [19, 20] and two prospective registry studies [21, 22] were included as 
the best available evidence.  
There was a lack of reporting on AEs in the included studies. The registry study with most patients 
(2000 patients) reported only on SAEs [22]. Each one of the three smaller studies reported on dif-
ferent AEs, skin rash/itching, false alarms and palpitations, light-headedness, and fainting, 
respectively [18, 19, 21]. Another study revealed that allergic contact dermatitis could be caused 
by metal hypersensitivity in the WCD use [64]. There are also some hints that compliance with the 
WCD use is connected to temperature i.e. less wear time in summer than in winter [65] that might 
also have an impact on the skin related AEs. Three out of five included studies reported on 
previous treatments [18, 19, 21], whereas it was not clearly stated in all studies if or which 
treatment patients received during the WCD use, which might have affected some of the 
outcomes (i.e. pharmacological therapy might lead to side effects). 
The named AEs and SAEs were relevant for patients, but some might have been missed. 
Avoidance of an ICD might be more relevant for payers than for patients according to the results 
of the Focus group, where patients favoured the ICD. However, comparative studies are missing 
in order to assess the clinical effectiveness and safety with regard to comparators.  
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Discontinuation due to comfort and lifestyle issues could be due to several reasons: the WCD needs 
to be worn 24/7 and therefore affects daily life and routine, and there might be some restrictions 
doing sports or other leisure activities. Results of the Focus group show that patients would have 
some hesitations in using the WCD in public. User dependent harms could be in part connected to 
compliance and personal attitude. However, qualitative studies on HRQoL and satisfaction were 
missing.  
There is homogeneity in results with regard to unsuccessful shocks (in 0-0.7% of patients), 
inappropriate shocks (in 0-2% of patients), and frequency of SAEs leading to death (in 0-0.3% of 
patients). Other safety issues are bystander interference and unsuccessful shocks caused by 
signal disruption due to falling and wedging bodies [24]. However, inappropriate shocks might 
also vary per subgroup. The WCD has a higher risk of motion-related sensory artefacts than an 
ICD since it is placed outside of the body [6]. External noise detection could also lead to 
inappropriate shocks [23]. A fatal device-device interaction between an WCD and a unipolar 
pacemaker was observed in a patient using both technologies simultaneously. The study suggested 
that identification of these interactions in patients with congenital heart disease and poor cardiac 
function is important because there is no access for placement of transvenous pacing leads due 
to the Fontan palliated single ventricle. Furthermore, children frequently have unipolar epicardial 
leads [46]. Also, a study showed that cellular telephones can interfere with medical equipment. 
However, only ZOLL Medical Corporation M-Series defibrillators (AED) were analysed, which 
showed no interference with cellular telephones [66]. Possible interactions with the WCD were not 
evaluated and therefore cannot be excluded.  
Double reporting was considered in the five studies, but seen as unlikely, since those studies  
whose study duration overlapped [19, 20, 22] were either performed in different countries, or had 
different inclusion criteria. One further prospective uncontrolled study (84 patients) was identified 
[67], but not considered due to several reasons: the study declared that one part of patients was 
included in the WEARIT/BIROAD study [18] and therefore included double reporting. Another 
reason was German language (which would not have allowed all assessment authors to read and 
check). Studies dealing with induced VT/VF in a hospital setting were also disregarded [39, 47].  
It must be noted that ICDs are also subject to inappropriate shocks, which may arise from an ICD 
sensitivity to atrial fibrillation (AF), supraventricular tachyarrhythmias, sinus tachycardia, and 
benign VAs that would otherwise self-terminate in the absence of a shock. This could be 
overcome by changing the settings in order to reduce the sensitivity of the device’s sensing 
mechanism [68].  
Furthermore, it should be kept in mind that comparators do have other specific harms, which the 
WCD does not have. In case of ICDs, these are device infections (pocket infection, deeper 
infection) [38] and procedure related complications including deaths and right ventricular 
perforation. Pharmacological therapy has side effects especially in elderly patients [69]. Possible 
complications of catheter ablation are stroke, valve damage, cardiac tamponade, atrio-ventricular 
block (AV) and procedure-related mortality [1]. 
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7 PATIENT INVOLVEMENT 
Results and integration into HTA 
Ten patients (nine men and one woman) replied to the request from the standardised email (see 
METHODS AND EVIDENCE INCLUDED). The woman received a heart transplant recently and 
therefore was not able to make the journey to the premises of LBI-HTA in Vienna (Austria), where 
the Focus group meeting was held. Finally, five patients were available at the proposed timeslot 
and agreed to participate. Four patients were from Austria (one from Lower Austria, Styria, Upper 
Austria, and Vienna, respectively) and one patient from Germany (Bavaria). All patients have 
received a heart transplant in the past and four patients have had an ICD at some point before. 
Men were aged between 55 and 73 years (mean 65).  
No patient had an experience with using a WCD or was familiar with this technology. Patients were 
properly prepared to explain their disease history. The majority of patients were exercising com-
petitive sports. Furthermore, since only men participated in the Focus group, no gender-depend-
ent issues could be evaluated. 
Views on patient relevant endpoints were identified:  
 Avoidance of an ICD implantation: Patients highlighted the sense of security they 
experienced through the use of an ICD, because patients were facing fear and anxiety 
due to their heart disease (fear of diagnosis itself, of reduced physical performance, of 
repeatedly having symptoms, of worsening, of death – when having a family and 
responsibility, for the future). All concluded that feeling of security was crucial. One 
patient stated that the ICD was like a “life insurance”. 
 HRQoL: Patients who had an ICD were able to do sports and to live a normal life with 
few/no limitations in everyday life (e.g. independent mobility), which was of the utmost 
importance to them. 
 Inappropriate/unsuccessful shocks: Patients reported on having received shocks by the 
ICD at several occasions, which differed in strength and impact on the body. Furthermore, 
several complications with ICD devices were described. Patients disclosed that receiving 
a defibrillation shock was terrifying. 
 All patients felt that the waiting times for heart transplants were far too long although they 
acknowledged the scarcity of heart transplants. They agreed that since they have had 
received their transplant, their QoL improved dramatically. 
Towards the end of the Focus group, the WCD was explained and presented, and  
patients were asked to comment on their attitude with regard to the WCD and to pose questions: 
 Compliance: Most patients could image using the WCD on a short term basis, but stated 
that it would be less of an option for long-term use due to the efforts of wearing it (especially 
in warm weather). Furthermore, its possible weight was mentioned as an issue as well.  
 HRQoL: Patients would feel restricted in their working life, when driving a car, or doing 
sports, and would fear removing the WCD. Patients stated that they do not want to be 
constantly reminded of their disease – at some point one forgets of having an ICD, which 
however is not possible when wearing the defibrillator – and that they do not want to 
exhibit it to others in public. One patient described his inferior QoL with external 
components of the technology (i.e. with an artificial heart). 
 Patients not having any experience with using the WCD reported that they have some res-
ervations towards the WCD. Their trust in the ICD would be higher than in the WCD. The 
response button, which is integrated in the WCD, was a big topic of discussion. Patients 
declared that they would be afraid of unintentionally deactivating it and of not wanting to 
have the responsibility of deciding whether to push the response button or not, because 
they assumed that they do not have the knowledge and the decision-making competence 
as clinicians do. 
 Furthermore, patients asked whether the WCD has pacing capabilities, which it does not 
have. 
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8 POTENTIAL ETHICAL, ORGANISATIONAL, PATIENT AND SOCIAL, 
AND LEGAL ASPECTS (ETH, ORG, SOC, LEG) 
8.1 Research questions 
Element ID Research question 
Ethical assessment elements 
F0010 What are the known and estimated benefits and harms for patients  
when implementing or not implementing the WCD? 
F0011 What are the benefits and harms of the WCD for relatives and care givers? 
F0012 How does implementation or withdrawal of the WCD affect the distribution  
of health care resources? 
F0104 Are there any ethical obstacles for evidence generation regarding the benefits 
and harms of the WCD? 
F0017 What are the ethical consequences of the choice of endpoints, and 
comparators in the assessment? 
F0005 Is the WCD used for individuals that are especially vulnerable? 
Organizational assessment elements 
G0002 What kind of involvement has to be mobilised for patients/doctors and/or 
caregivers?  
G0003 What kind of process ensures proper education and training of staff?  
H0203 What specific issues may need to be communicated to patients to improve 
adherence? 
G0004 What kinds of co-operation and communication of activities have to be mobilised?  
H0002 What is the burden on care-givers? 
G0101 What are the processes ensuring access to the WCD for patients/participants?  
G0009 Who decides which people are eligible for WCD and on what basis?  
H0012 Are there factors that could prevent a group or person from gaining access  
to the WCD? 
G0012 In what way is the quality assurance and monitoring system of the WCD 
organised?  
Patient and Social assessment elements 
H0200 What are the experiences of living at risk of SCA? 
H0100 What expectations and wishes do patients have with regard to the WCD;  
what do they expect to gain from the technology? 
H0006 How do patients perceive the WCD? 
Legal assessment elements 
I0026 What should be known about the legal issues in the case of WCD  
where the current legislation is not directly applicable? 
F0101 Does the WCD invade the sphere of privacy of the patient? 
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8.2 Results 
Ethical assessment elements 
F0010 – What are the known and estimated benefits and harms for patients  
when implementing or not implementing the WCD? 
F0011 – What are the benefits and harms of the WCD for relatives and care givers? 
F0012 – How does implementation or withdrawal of the WCD affect  
the distribution of health care resources? 
In the analysis of the ethical implications of the WCD, the principles of beneficence and non-ma-
leficence have to be weighted. The WCD promises to offer manifold benefits for patients at risk of 
SCA awaiting an ICD, a heart transplant, response to pharmacological therapy, or response to 
catheter (radiofrequency) ablation. As with many other new technologies – due to the lack of good 
quality evidence – the uncertainties of the realisation of the promise have to be balanced against 
the psychological benefit of the feeling of certainty and the possibility for patients to live in their 
normal environment [5]. These highly subjective benefits must be contrasted with some smaller 
harms (skin rash, itching, false alarms, palpitations, light-headedness, fainting), but also with serious 
harms (inappropriate shocks and/or unsuccessful shocks) that may induce further arrhythmias and 
possibly lead to death – leading to psychological stress and fear or anxiety of technical 
malfunctions [70]. 
The eventual autonomy and freedom gained in living a normal life through moving in the out-of-
hospital setting needs to be balanced against the patient ’s responsibility of having to decide be-
tween appropriate or inappropriate shocks. The feature of using response buttons in order to 
prevent inappropriate shocks is claimed to be the WCD’s benefit, but results from the discussion 
with patients in the scoping phase point to the contrary. Patients that would have qualified – 
prior to their heart transplantation and partly had an ICD – for a WCD unanimously stated that 
they would not want to have the responsibility for pushing the response button in order to prevent 
an inappropriate shock in the fear of possibly preventing an appropriate therapy. They could 
imagine using the WCD for short term protection, but implantation of an ICD was undoubtedly the 
preferable option. This is also supported by research in other areas of disease that shows that 
65% of healthy surveyed individuals state that if they had cancer, they would want to choose their 
treatment, however, only 12% of cancer patients want to choose their mode of treatment [71]. 
According to Gewande, this discrepancy points to the fact that patients do not value autonomy 
when their life is in danger, but they rather expect competence on behalf of the medical staff 
[71]. Furthermore, the autonomy is provided at the expense of false security as the patient’s 
understanding of the technology presupposes total protection from lethal arrhythmias and not just 
protection from VT and VF. 
The principle of beneficence and non-maleficence can be reflected about not only for patients, but 
also for relatives and care-givers. On the one hand, the WCD allows the relatives to spend more 
time with the patient, yet on the other hand, the relatives and caregivers are in the position of hav-
ing to face the possible psychological harm that stems from their need to bear responsibility over 
the intervention as they are in the position of having to react by pressing the response buttons if 
needed. Furthermore, the fact that both relatives and caregivers are advised to be present 
whenever the patient takes the garment off [4] may also contribute to a psychological harm 
caused by fear or anxiety.  
Against the backdrop of the limited knowledge about the right candidates for the technology and a 
rather big indication group, an issue arises with respect to the principle of distributional justice of 
investing resources in technologies of unknown benefit while not spending the resources elsewhere. 
Additionally, offering protection (based on promises rather than evidence) to the patients at 
imminent risk of SCA might be considered unethical. A fair and just implementation of the WCD 
is dependent on the risk stratification that drives it usage. Even though ZOLL Medical Corporation 
covers – for the time of market access – the costs for training of cardiologists as well as the 
maintenance of the device [5], indirect harm is done to the society in case there is too low of a risk 
for SCA and the resources could have been invested elsewhere. The use of the WCD hence 
gives rise to ethical issues with respect to principles of beneficence and justice because of its 
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wide base of indications that, due to its uncertain or marginal benefit and cost-effective reasons 
[72], may be difficult to be all covered in practice. 
 
F0104 – Are there any ethical obstacles for evidence generation  
regarding the benefits and harms of the WCD? 
F0017 – What are the ethical consequences of the choice of endpoints,  
and comparators in the assessment? 
The obstacle to conduct a comparative clinical trial in vulnerable patients (of various indication 
groups) that would be hospitalised due to their physical condition could be overcome by offering 
the WCD (compared for instance to pharmacological therapy) in a controlled and monitored 
setting, so that AEs of any intervention could be reacted to fast.  
The chosen endpoints – LVEF improvement, reduction of hospitals stays, or avoidance of ICD im-
plantation might not be the endpoints relevant to patients. According to the discussion in the Focus 
group, QoL, including freedom from anxiety or the ability to perform activities of daily living 
including sports, is of high importance. The endpoint of avoidance of an ICD implantation ought 
to be explored more in order to find out if it is a patient relevant endpoint. The reason is that 
based upon the results from the Focus group, where four patients were once implanted with an 
ICD, there was no negative reaction associated with an ICD implantation. This suggests that 
avoidance of an ICD implantation is not necessarily a patient relevant endpoint as the Focus 
group patients suggested that they see the WCD as a solution for a very short term until the ICD 
is implanted and not as an alternative (as the WCD claims to be for instance in the period post 
MI), due to the fact that the protection provided by the ICD is far greater and it bears with itself far 
less responsibility.  
Due to the fact that patients with an LVEF improvement at the end of the WCD use, which lead to 
the avoidance of an ICD implantation, died of VT or VF post WCD use [21], the endpoint of the 
LVEF improvement may leave a segment the population unprotected. The fact that a patient ’s 
LVEF improves does not mean that the LVEF cannot deteriorate again and hence that the ICD is 
not needed. 
 
F0005 – Is the WCD used for individuals that are especially vulnerable? 
The patients potentially qualifying for the WCD are all at risk of SCA and therefore vulnerable due 
to their physical, but also their psychological condition (fear, anxiety). Particularly vulnerable are  
the patient groups of peri- and post-partum women where their unborn, or recently born, child re-
quires mother’s care, and older patients with various cardiac comorbidities, who can have reduced 
decision-making capacity and be cognitively impaired. The WCD is also used in children (since the 
FDA approval in 2015) that are an especially vulnerable group. 
 
Organizational additional elements 
G0002 – What kind of involvement has to be mobilised  
for patients/doctors and/or caregivers?  
G0003 – What kind of process ensures proper education and training of staff?  
H0203 – What specific issues may need to be communicated to patients  
to improve adherence? 
G0004 – What kinds of co-operation and communication of activities have to be mobilised? 
H0002 – What is the burden on care-givers? 
The introduction of the WCD requires involvement of the patient, their family or caregivers, the  
cardiologist, and the manufacturer (for maintenance) [5]. With the WCD, the tasks that would be 
otherwise carried out by health care professionals are moved into responsibility of the patient.  
Therefore, patients and their caregivers need to be trained how to use the WCD and, for the sake 
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of a successful treatment, comply with the instructions. All are possibly involved in the delivery of 
the treatment, as the relatives and caregivers are advised to be present when the patient puts the 
WCD off, and post-treatment, as the patient needs medical treatment post-shock [6].  
Patients need to be made aware that complying with the technology requires them to follow a list 
of instructions from the daily changing and charging of the battery, to washing of the garments, 
placing of the electrodes, and pressing the response buttons if needed [5].  
The WCD does not require new kinds of professionals, but it does require the existing personnel 
to perform new tasks. It requires the cardiologist to monitor and review the patient’s data collected 
by the device, which may enhance the patient-doctor relationship. It also requires caregivers to help 
patients with reduced cognitive capacity to comply with the technology. Proper training on the use 
of the WCD, especially in terms of compliance, might be crucial for good outcomes. As described, 
implementing of the WCD requires new cooperation between cardiologists and patients, 
cardiologists and the manufacturer, and patients and the manufacturer. 
 
G0101 – What are the processes ensuring access to the WCD for patients/participants?  
G0009 – Who decides which people are eligible for WCD and on what basis?  
H0012 – Are there factors that could prevent a group or person  
from gaining access to the WCD? 
Processes insuring access to the WCD are that upon diagnosis, patients receive the device and 
they are expected to wear it for most of the day (apart from taking a shower/bath or changing the 
garment) [5]. The studies included in the assessment suggest a high compliance in terms of the 
device utilisation (see Table 7: Characteristics of included studies in Appendix 1). 
The key actors that decide on the use of the technology are, on the macro level, the funding bodies 
and on the micro level, respective cardiologists. The decision to use a WCD is made upon 
diagnosis of the patient’s risk of SCA, especially if the patient’s diagnosis falls under the list of 
indications outlined above. 
Factors that would prevent a group or a person from gaining access to the WCD depend on the 
price of the device in the respective health care system and the question of patient co-payments, 
which would make the device accessible only to the financially better-off groups. Also, due to the 
price of the device, as perceived also by the physicians, the question of cost-effectiveness2 of the 
WCD for a Quality Adjusted Life Year and cost-effectiveness thresholds of different countries may 
make the device hard to access [72, 73].  
Furthermore, potential geographical discrimination may be caused by the need to pay a hospital 
visit post-shock or alternatively, there is a possibility of a gender-related discrimination and stig-
matisation due to the fitting of the garment in the chest area of the body. 
 
G0012 – In what way is the quality assurance and monitoring system  
of the WCD organised?  
The main responsibility for quality assurance and maintenance is currently on ZOLL Medical 
Corporation. The WCD is a rental device and it is returned after patient’s use for cleaning and 
testing of the device, with reconditioning or repair completed when required. Devices must pass 
an inspection and testing process in order to be sent to another patient. At this point in time during 
the market introduction phase, the costs of all maintenance and repair are defrayed by ZOLL 
Medical Corporation [5]. 
The maintenance needs and costs are not known yet. Such system of centralised monopolistic 
quality assurance looks effective, but gives reasons for concern to see whether in peripheral 
geographic regions and in remote areas such quality service is also delivered to patients that are 
                                                     
2
 In the absence of any effectiveness data, assumptions about the device’s cost-effectiveness are made based upon the 
marginal effect of the WCD in the included studies with larger cohorts (less than 2%) (see Table 7: Characteristics of 
included studies in Appendix 1) and the published cost-effectiveness analyses as referenced above. 
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not in the ZOLL Medical Corporation distribution countries, as the WCD system and services are 
provided by trained distributors in Sweden and the UK [5]. 
 
Patient and Social assessment elements 
H0200 – What are the experiences of living at risk of SCA? 
Majority of the endangered population are patients at high risk of CAD who have not had clinical 
events and hence live with the danger of SCA unaware [10]. Reflections from those patients that 
survived an SCA event (and so remained to be at risk of further SCAs) include following themes: 
feelings of insecurity that the heart is not functioning as expected and the need for support. SCA 
survivors emphasise the need to receive all the health care available [74]. Further themes are: 
striving to regain former life, being active, fulfilling one’s role; gaining a new perspective on life that 
makes SCA survivors engage in a comprehensive re-evaluation of habits and priorities with the 
goal of reducing stress and living a healthier life; and going through emotional challenges of fear 
and anxiety [74]. SCA survivors seem to experience fore-warning symptoms such as heartburn or 
decreased endurance for hours, days, or even years before the arrest, but pay little attention to  
them [74]. 
 
H0100 – What expectations and wishes do patients have with regard to the WCD;  
what do they expect to gain from the technology? 
H0006 – How do patients perceive the WCD? 
Patient expectations include protection from lethal arrhythmias and the ability to remain protected 
outside of hospital. Compared to alternative interventions, the WCD allows patients to return to 
home and participate in their social life sooner. Based upon the Focus group results, it is expected 
that possible issues arising as a consequence of using the technology may be worries about 
pressing response buttons, anxiety from inappropriate shocks, hope to remain protected during the 
period of wearing the WCD, and the above mentioned issue of stigmatisation (see H0012). The 
side effects that seem most difficult to manage are skin related side effects, which may lead to 
allergic dermatitis [64], and comfort and lifestyle related side effects that are most recurrent. 
It can be assumed that the patient’s understanding of the technology presupposes total protection 
from lethal arrhythmias and not just a protection from VT and VF. Patients use the only WCD on 
the market called LifeVest®, name that supports the assumption that the vest will save the patient 
in a life threatening situation, yet such tangible insurance protects the patient only from the 
particular lethal arrhythmias.  
 
Legal assessment elements 
I0026 – What should be known about the legal issues in the case of WCD  
where the current legislation is not directly applicable? 
F0101 – Does the WCD invade the sphere of privacy of the patient? 
In the analysis of legal issues in the case of an WCD, protection of private data and liability need to 
be highlighted. The WCD does invade the sphere of privacy through gathering of information 
regarding the individual patient’s heart functions and through sending it to the respective 
cardiologists [5]. However, such handling of personal information may be justified if the benefit of 
the WCD is proven. Liability for AEs (skin rash, itching, false alarms, palpitations, light-
headedness, fainting), SAEs (inappropriate shocks and/or unsuccessful shocks), and issues 
connected with either of those, such as car accidents caused by inappropriate shocks, require 
the parties involved to take responsibility. Also, in the absence of comparative data and hence 
the promise of false security (as outlined in F0010), there is a potential issue with liability for 
harms inflicted on the side of authors, scientists, and the manufacturer. 
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APPENDIX 1: METHODS AND DESCRIPTION OF THE EVIDENCE USED 
 
DOCUMENTATION OF THE SEARCH STRATEGIES  
 
Search strategy for Cochrane on 14/07/2016 
ID Search 
#1 “life vest“ (Word variations have been searched) 
#2 lifevest* (Word variations have been searched) 
#3 lifecor  
#4 (wearable or portable) near (cardioverter* or defibrillator*) (Word variations have been searched) 
#5 wcd:ti,ab,kw (Word variations have been searched) 
#6 zoll:ti,ab,kw (Word variations have been searched) 
#7 #2 or #3 or #4 or #5 or #6 (#1 did not yield any results) 
22 Hits 
 
Search strategy for CRD on 14/07/2016 
1 (life vest*) 
2 (lifevest*) 
3 (lifecor*) 
4 ((wearable OR portable) NEAR (cardioverter* OR defibrillator*)) 
5 (wcd) 
6 (zoll) 
7 #2 OR #3 OR #4 OR #6 (#5 and #7 did not yield any results) 
6 Hits 
 
Search strategy for Embase on 14/07/2016 
No. Query Results Results 
#7. ‘life vest*’ OR lifevest* OR lifecor OR ((wearable OR portable) NEAR/2  
(cardioverter* OR defibrillator*)):ab,ti OR wcd:ab,ti OR zoll:df ........................................... 501 
#6. zoll:df ......................................................................................................................................................................... 175 
#5. wcd:ab,ti .................................................................................................................................................................. 204 
#4. ((wearable OR portable) NEAR/2 (cardioverter* OR defibrillator*)):ab,ti ..................... 224 
#3. lifecor ............................................................................................................................................................................20 
#2. lifevest* .......................................................................................................................................................................75 
#1. ‘life vest*’ ....................................................................................................................................................................47 
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Search strategy for Medline on 14/07/2016 
1 life vest*.mp. (22) 
2 lifevest*.mp. (9) 
3 lifecor.mp. (2) 
4 ((wearable or portable) adj5 (cardioverter* or defibrillator*)).mp. (121) 
5 wcd.ti,ab. (96) 
6 zoll.ti,ab. (82) 
7 1 or 2 or 3 or 4 or 5 or 6 (276) 
8 remove duplicates from 7 (274) 
 
Search strategy for identification of ongoing clinical trials on 31/08/2016 
ClinicalTrials.gov 
(life vest* OR lifevest* OR lifecor OR wearable cardioverter* OR wearable defibrillator* OR  
portable cardioverter* OR portable defibrillator* OR wcd) [TREATMENT] 
15 Hits 
WHO ICTRP (Basic Search Mode) 
life vest* OR lifevest* OR lifecor OR wearable cardioverter* OR wearable defibrillator* OR  
portable cardioverter* OR portable defibrillator* OR wcd  
13 Hits 
EudraCT 
No additional studies identified 
Search strategy for Guidelines on 19/09/2016 
G-I-N: 
Search String: (life vest* OR lifevest* OR lifecor OR wearable cardioverter* OR  
wearable defibrillator* OR portable cardioverter* OR portable defibrillator* OR wcd) 
0 Hits 
National Guidelines Clearinghouse:  
Search String: ((portable OR wearable) AND (cardioverter* OR defibrillator*)) OR wcd OR  
lifecor OR lifevest OR “Life Vest“ 
15 Hits 
TRIP-Database 
((wearable OR portable) AND cardioverter) OR wcd OR lifevest OR lifecor 
67 Hits 
Hits in total (15 + 62) = 82  
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Semi-structured interview questions for Focus group participants (please note that the Focus group 
was held in German i.e. the questions were posed in German) 
This is a set of questions for patients who were diagnosed with any indication(s) that may lead to 
SCA, but who have not been treated with the LifeVest®. 
 
A) Engagement questions 
 
 1. Could you tell us about yourselves? 
  a. What are the heart problems that you have had? 
  b. How did you find out about that? 
c. What did a day in your life with these heath challenges before the heart  
transplant look like?  
 d. What help did you need (relatives, care givers, doctors)? 
 
B) Exploration questions 
 
 2. Which treatment options have you and your doctor considered? 
  a. Could you rank those treatments from best to worst? 
  b. What made them better/worse? (AEs, effectiveness, distress, self-care,  
capacity to work) 
c. If hospitalisation was needed, what did it look like? 
d. How difficult were the treatments to follow in practice? 
e. What could have been improved? 
 
3. What would you think about a wearable defibrillator?  
a. Could you imagine wearing it while awaiting heart transplant? Why? 
b. For those who wore an Implantable Defibrillator, what was your experience like? 
c. For those who wore an Implantable Defibrillator, can you imagine wearing  
a wearable defibrillator instead? Why? 
 
C) Exit question 
  
4. Is there anything else that you would like to say about your experience of living  
with your health condition? 
 
FOCUS GROUP QUESTIONS 
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Table 5: Overview of guidelines 
Name of society/organisation  
issuing guidance 
Date of issue Summary of recommendation Class of 
recommendation/Leve
l of evidence* 
ESC Guidelines for the Diagnosis and Treat-
ment of Acute and Chronic Heart Failure [28] 
20 May, 2016 
(epub) 
A wearable ICD may be considered for patients with heart failure who are 
at risk of SCA for a limited period or as a bridge to an implanted device. 
II b/C  
WCD Therapy for the Prevention of SCD – 
A Science Advisory From the AHA [7] 
28 March, 2016 
(epub) 
Use of WCDs is reasonable when there is a clear indication for an 
implanted/permanent device accompanied by a transient 
contraindication or interruption in ICD care such as infection. 
II a/C  
Use of WCDs is reasonable as a bridge to more definitive therapy 
such as cardiac transplantation. 
II a/C  
Use of WCDs may be reasonable when there is concern about a height-
ened risk of SCD that may resolve over time or with treatment of left 
ventricular dysfunction; for example, in ischaemic heart disease with 
recent revascularization, newly diagnosed NICM in patients starting 
GL directed medical therapy, or secondary cardiomyopathy 
(tachycardia mediated, thyroid mediated, etc.) in which the underlying 
cause is potentially treatable.  
II b/C  
WCDs may be appropriate as bridging therapy in situations associated 
with increased risk of death in which ICDs have been shown to reduce 
SCD but not overall survival such as within 40 d of MI.  
II b/C  
DESCRIPTION OF THE EVIDENCE USED  
Guidelines for diagnosis and management  
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WCDs should not be used when non-arrhythmic risk is expected to 
significantly exceed arrhythmic risk, particularly in patients who are not 
expected to survive >6 mo. 
III/C  
2015 ESC Guidelines for the management 
of patients with ventricular arrhythmias and 
the prevention of SCD [1] 
29 August, 2015 
(epub) 
The WCD may be considered for adult patients with poor LV systolic 
function who are at risk of sudden arrhythmic death for a limited period, 
but are not candidates for an ICD (e.g. bridge to transplant, bridge to 
transvenous implant, peri-partum cardiomyopathy, active myocarditis 
and arrhythmias in the early post-MI phase).  
II b/C  
ICD implantation or temporary use of a WCD may be considered 40 
days after MI in selected patients (incomplete revascularization, pre-
existing LVEF dysfunction, occurrence of arrhythmias 48 h after the 
onset of ACS, poly-morphic VT or VF).  
II b/C  
WCD should be considered for bridging until full recovery or ICD  
implantation in patients after inflammatory heart diseases with residual 
severe LV dysfunction and/or ventricular electrical instability.  
II a/C  
German Cardiac Society – Statement on 
the use of the WCD [30] 
27 February, 2015 
(epub) 
In patients immediately after explantation of an ICD, if an immediate 
reimplantation of an ICD is not possible. 
II a/C 
In patients on a waiting list for a heart transplant without an ICD. II a/C 
If LVEF not yet finally assessed, if heart failure with LVEF ≤ 35% is 
detected but no permanent risk for SCD yet assessed i.e: 
 Expected improvement of LVEF in patients with myocarditis  
or in patients with newly diagnosed dilated cardiomyopathy or 
with supposed tachymyopathy if dysrhythmia can be removed 
 In patients with expected improvement in consequence of  
peri-partum cardiomyopathy  
 In patients within four weeks after revascularisation by means 
of percutaneous coronary intervention and within 90 days after 
revascularisation by means of coronary artery bypass surgery 
 In patients with secondary prophylactic ICD indication when 
diagnostics not yet finalised 
 In patients within 40 days of MI 
II b/C 
In patients with terminal non-cardiac disease III/- 
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In patients who refuse an ICD therapy due to personal reasons III/- 
AHA/ACC/HRS – Expert Consensus 
Statement on the Use of ICD Therapy in 
Patients Who Are Not Included or Not Well 
Represented in Clinical Trials [75] 
9 May, 2014 
(epub) 
Two statements are made (no level of evidence indicated): 
 The WCD may be an option as a “bridge to ICD” for selected 
patients at high risk of SCD due to VAs, although the data are 
scant. 
 The WCD may play a role in patients at risk of SCD in the  
early period after re-vascularization. 
-/- 
EHRA/HRS/APHRS –  
Expert consensus on ventricular  
arrhythmias [76] 
30 August, 2014 
(epub) 
Two statements are made (no level of evidence indicated): 
 Patients who have impaired LV systolic function after MI 
(LVEF ˂0.35) are at higher risk of sudden death in the first  
3 months and may benefit from a WCD. 
 Patients who are treated with coronary revascularization after 
MI are also at risk, especially if the LVEF is ˂0.35. These patients 
may also benefit from a WCD with reassessment of LV function 
and the indication for an ICD at 90 days post-revascularization. 
-/- 
German paediatric cardiac society – guide-
line on myocarditis (in children and youth) 
[77] 
13 June, 2012 One statement is made (no level of evidence indicated): 
In life threatening tachyarrhythmia, a temporary use of a LifeVest® or 
an AED instead of an ICD could be considered. 
-/- 
Transvenous Lead Extraction: Heart 
Rhythm Society Expert Consensus on 
Facilities, Training, Indications, and Patient 
Management – endorsed by AHA [78] 
22 May, 2009 
(epub) 
One statement is made (no level of evidence indicated): 
When there is concern for ongoing infection, alternatives to early  
re-implantation (after 2–3 days) include WCDs, epicardial lead 
implantation and surgical debridement of vegetations. 
-/- 
Heart Rhythm Considerations in Heart 
Transplant Candidates and Considerations 
for Ventricular Assist Devices: International 
Society for Heart and Lung Transplantation 
Guidelines for the Care of Cardiac  
Transplant Candidates—2006 [79] 
September 2006 An implanted or wearable ICD should be provided for Status 1B 
patients who are discharged home given that the wait for 
transplantation remains significant. 
Furthermore the following statement is made: 
Use of WCDs can serve as a bridge to transplant. This is particularly 
true for patients with systemic or device infections or in patients whose 
anticipated waiting time to transplant is short, such as candidates with 
blood types A and B. 
-/C 
*For explanations of terms, see Table 6: Description of level of evidence and classes of recommendations [28] 
Abbreviations: ACC – American College of Cardiology; AED-Automated External Defibrillator; AHA-American Heart Association; APHRS-Asia Pacific Heart Rhythm Society; EHRA-European Heart 
Rhythm Association; ESC-European Society of Cardiology; epub-e-publication; GL-Guideline; HRS – Heart Rhythm Society; ICD-Implantable Cardioverter Defibrillator; LVEF-Left Ventricular Ejection 
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Fraction; MI – Myocardial Infarction; mo-month; NICM-Non-ischaemic Cardiomyopathy; VF-Ventricular Fibrillation; VT-Ventricular Tachycardia; SCA-Sudden Cardiac Arrest; SCD-Sudden Cardiac Death; 
WCD-Wearable Cardioverter Defibrillator. 
Table 6: Description of level of evidence and classes of recommendations [28] 
   
 
 
  
 WCD therapy for prevention of SCA 
Version 1.4, November 2016 EUnetHTA JA3 WP4  57 
 
Table 7: Characteristics of included studies  
 
Interventional  
single arm study 
Prospective case series  Prospective  
registry studies 
 
 Feldman 2004 [18] Duncker 2014 [19] Kondo 2015 [20] Kao 2012 [21] Kutyifa 2015 [22] 
Study characteristics 
Study name WEARIT/BIROAD NA NA WIF WEARIT-II 
Author Feldman et al. Duncker et al. Kondo et al. Kao et al. Kutyifa et al. 
Year of publication 2004 2014 2015 2012 2015 
Study registration 
number (register 
identifier) 
NA NA NA NA NA 
Country/ies of recruitment United States, Germany Germany Germany United States United States 
Sponsor ZOLL Medical Corporation ZOLL Medical Corporation unclear3 ZOLL Medical Corporation  ZOLL Medical Corporation 
Comparator none none none none none 
Study design Interventional single arm 
study 
Single-centre prospective 
case series 
Single-centre prospective 
case series 
Multi-centre 4prospective 
registry 
Multi-centre prospective 
registry 
Study duration (start and 
completion date) 
NA5 09/2012-09/2013 08/2010-11/2014 07/2007-02/2010 08/2011 – 02/2014 
                                                     
3
 source of funding not stated 
4
 10 centres 
5
 Feb 1998 to July 2001 according to FDA approval document 80. U.S. Food and Drug Administration. Premarket Approval (PMA). 2016 [cited 22/08/2016]; Available from: 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P010030. 
Evidence tables of individual studies included for safety 
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Objectives To assess the effectiveness 
of the WCD in patients at 
high risk for lethal VAs. 
1. To assess the 
usefulness of the WCD to 
bridge a potential risk for 
life-threatening arrhythmic 
events in patients with early 
PPCM, severely reduced 
LVEF, and symptoms of 
heart failure. 
1. To describe the utility of 
the WCD therapy in early 
post-MI phase. 
1. To collect SCA events, 
WCD defibrillation efficacy, 
and WCD usage data in 
heart failure patients. 
1. Characterise pts 
currently prescribed with 
WCD. 
2. Assess the risk for 
sustained VT events 
among WCD pts by disease 
aetiology. 
3. Identify the rate of EF 
improvement and the need 
for subsequent ICD 
implantation. 
Model version of 
technology 
WCD 20005 NA NA NA NA 
Patient characteristics 
Number of pts  2896 127 248 899 2000 
Age in yrs (range)±SD 5510 (18-75)±12 34 mean±4 69 mean±12 61.0(37-83) mean±11.1  62 median±16 
Sex (female/male) 52/237 12/0  2/22 25/64 598/1402 
EF in % (range)±SD 23±10 24.3 mean±11.611 30 (20-36) median  23.9 (7.5-65) mean ±9.4 25 median±10 
                                                     
6
 177 pts in WEARIT and 112 in BIROAD 
7
 WCD recommended to 9/12 pts, 2 refused, hence data available on 7 pts 
8
 66 consecutive patients of whom 24 (36%) were in the early post MI phase 
9
 out of 89 pts, data on 82 pts collected, 4 pts lost to follow-up, 3 pts dropped out after wearing the WCD for a couple of hours 
10
 in an unspecified statistical measure 
11
 unclear, as the number 24.0±11.8% also reported in the paper 
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Inclusion criteria 
 
WEARIT: Pts≥18-75 yrs, 
high risk of SCA, not 
eligible for ICD or waiting 
for ICD, ambulatory pts with 
NYHA Class III and IV and 
an LVEF <0.30 
BIROAD: Post MI with VT 
within 48 hrs and LVEF<0.30 
at least 3 d post MI or SCA 
or syncope at least after  
48 hrs post MI but not  
candidates for an ICD. VT 
within 48 hrs post CABG 
and LVEF<0.30 at least 3 d 
after CABG, had SCA or 
syncope after 48 hrs post 
CABG, but were unable to 
receive an ICD, ICD 
candidates at home waiting  
4 mos+, refused ICD 
Pts with newly diagnosed 
PPCM 
Pts with high risk of SCA 
but not eligible for 
immediate implantation of 
an ICD 
Pts in early post-MI phase 
Pts listed (or being 
considered) for heart 
transplantation, pts with 
dilated CM (with VT or EF ≤ 
40%), pts receiving 
inotropes 
Low EF and high risk of 
SCA post MI or post 
coronary revascularization 
or new onset non-
ischaemic DCM or high risk 
for SCA until stabilisation or 
inherited or congenial heart 
disease 
Exclusion criteria Inability to use WCD (i.e., 
chest circumference <28 or 
>48’’), advanced directive 
prohibiting resuscitation, 
participation in another 
clinical trial, not seen at 
least daily by a companion 
or caregiver, inability to 
provide informed consent, 
or non-cardiac terminal 
illness 
NA NA Pts with an active ICD or 
unable to use WCD due to 
impairment 
NA 
Follow-up time in months 
(range), mean±SD 
unclear12 10.4±3.4 (8.4–12.4)13 8 median (4-16) 3 2.914 
                                                     
12
 pts followed biweekly and monthly, but no last follow-up stated 
13
 81 days (25-345) in 7 women receiving a WCD 
14
 at 1, 3 and 12 months (12 month follow-up ongoing at time of paper)  
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Loss to follow-up, n (%) 68 (23.5) 0 NA 7 (8) NA 
Diagnosis   Heart failure, awaiting ICD, 
post MI, post SCA, post 
syncope, post CABG 
Newly diagnosed PPCM ST elevation, PCI, CABG 
 
Dilated CM with low EF 
(<40%) 
(Non-)ischaemic DCM, 
congenial/inherited heart 
disease 
Previous treatments Beta-blockers, AADs,  
Inotropes 
Beta-blockers, ACE  
inhibitors, Mineralocorticoid 
receptor antagonists,  
Bromocriptine 
NA Active pacemaker, Past/ 
inactive pacemaker, Prior/ 
inactive ICD 
Beta Blockers, ACE 
inhibitors, ARBs, Anti-
arrhythmics (Amiodarone), 
Inotropes 
NA 
Outcomes  
Efficacy (data were extracted but not used for assessment of effectiveness) 
Mortality n (%) 
 All-cause 
mortality 
 Disease-specific 
mortality(preven
tion of SCA) 
 
12 (4.2) 
 
615 (2.1) 
 
0 
 
0 
 
016 
 
0 
 
017 
 
0 
 
3 (0.2)18 
 
0 
Incidence of VT/VF n/in n 
(%) pts 
 Appropriate 
shocks 
 Withheld shocks 
NA 
 
6/4 (1.4) 
 
NA 
4/3 (43) 
 
4/3 (43) 
 
NA 
3/2 (8) 
 
3/2 (8)  
 
NA 
NA 
 
NA 
 
NA 
120/41 (2.1) 
 
30/22 (1.1) 
 
90/22 (1.1) 
First shock success (%) NA 100 100 NA 100 
HRQL NA NA NA NA NA 
Hospitalisation rate NA NA NA NA NA 
                                                     
15
 5 pts were not wearing the device – 4 were non-compliant due to size and weight of WCD and 1 pt reversed the device leads that lead to an unsuccessful shock 
16
 2 patients (8.3%) had a fatal non-arrhythmic event within 3 months after MI 
17
 after WCD use, 6 pts died of unknown causes 
18
 due to an asystole event and none due to VT/VF 
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Satisfaction with  
technology 
NA NA NA NA NA 
Compliance/patient  
adherence 
 WCD wear-time in 
d (range), median  
 WCD daily use  
in hrs (range), 
median 
 
 
94 mean 
 
NA 
 
 
81 (25–345) 
 
22 (16.3-23.6) mean±2.4  
 
 
33 (20-67)19 
 
23.1 (21.6-23.6) 
 
 
79 (1-277)20 
 
21.8 (3.7-23.7)21 
 
 
90 
 
22.5 
Avoidance of ICD  
implantation22 (%) 
NA unclear23 unclear24 unclear25 40 
% of improvement in EF 
in mean±SD(range) 
NA 22.5±9.7 (16.8–28.3) 5 median26 13.5±15.727  NA 
                                                     
19
 1 pt was excluded because of irregularities in device use 
20
 2 pts were still wearing the device at the end of the study 
21
 calculated based on pts who wore the device for 7 days or greater (n=75) 
22
 WCD is not only a bridge to an ICD implantation 
23
 66.6% of pts without implanted ICD however, PPCM is “associated with up to 90% recovery after causative factors are removed”, hence avoidance of ICD implantation is not 
directly associated to the success of the WCD (see reference: 81. Sperzel J. Value of the wearable cardioverter defibrillator (WCD) as a bridging-therapy before implantation 
of a cardioverter defibrillator (ICD). Journal of Atrial Fibrillation. 2016;8(5):93-8.) 
2 pts who experienced VF events and shock delivery underwent secondary prophylactic ICD/CRT-D implantation after these events. The third patient has been wearing the WCD 
for one year and refuses ICD implantation. Eight patients who did not have arrhythmic events during follow-up and had demonstrated impressive improvement of LVEF with 
reduction of heart failure symptoms did not receive ICD. One patient underwent CRT-D implantation for primary prevention due to persistently reduced LVEF 
24
 42% of pts without implanted ICD however, ICD implantation during 40 d post MI is not recommended by guidelines, hence avoidance of ICD implantation might not directly be 
associated to the success of the WCD 
25
 at WCD discontinuation: 41.4% of pts were considered much improved due to improved EF (defined as EF≤35%), acute allograft rejection resolved, or feeling better and one 
unknown reason. 34.1% went on to receive an ICD implant. Not receiving an ICD does not imply a WCD’s success as presumably not all pts were indicated for an ICD. 
26
 from baseline 30% (20–36%) to 35% (25–40%) 
27
 final data from 70/89 pts 
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Safety 
AEs in n (%) of pts 
 Skin rash and 
itching 
 False alarms 
 Palpitations, ligh-
theadedness, and 
fainting 
Frequency of 
discontinuation due to 
AEs in n (%) of pts 
 Discontinuation 
due to comfort 
and lifestyle issues 
Frequency of unexpected 
AEs in n (%) of pts 
SAEs in n (%) of pts 
 Inappropriate 
shocks 
 Unsuccessful 
shock 
Frequency of SAEs  
leading to death in n (%) 
of pts 
 
17 (6) 
 
NA 
 
NA 
 
 
 
 
 
65 (22)28 
 
 
NA 
 
 
6 (2) 
 
2 (0.7)29 
 
 
1 (0.3)30 
 
NA 
 
1 (14)31 
 
NA 
 
 
 
 
 
NA 
 
 
NA 
 
 
0 
 
0 
 
 
0 
 
NA 
 
NA 
 
NA 
 
 
 
 
 
NA 
 
 
NA 
 
 
0 
 
0 
 
 
0 
 
NA 
 
NA 
 
7 (9) 
 
 
 
 
 
13 (16)32  
 
 
NA 
 
 
0 
 
NA 
 
 
0 
 
NA 
 
NA 
 
NA 
 
 
 
 
 
NA 
 
 
NA 
 
 
10 (0.5)33 
 
0 
 
 
0 
Abbreviations: AAD-Anti-Arrhythmic Drug; ACE- Angiotensin-converting Enzyme; AE-Adverse Events, CABG-Coronary Artery Bypass Grafting; CM-Cardiomyopathy; d-days; DCM-Dilated 
Cardiomyopathy; ECG-Electrocardiogram; EF-Ejection Fraction; HRQL-Health-Related Quality of Life; hrs-hours; ICD-Implantable Cardioverter Defibrillator; LVEF-Left Ventricular Ejection Fraction;  
MI-Myocardial Infarction; min-minute; NA-not available; NYHA-New York Heart Association; PM-Pacemaker; PPCM-Peri-partum Cardiomyopathy; pre-op-pre-operation; pt-patient; SAEs-serious adverse 
events; SCA-Sudden Cardiac Arrest, SD-Standard Deviation; V-ventricular; VF-Ventricular Fibrillation; VT-Ventricular Tachycardia; WCD-Wearable Cardioverter Defibrillator; yrs-years. 
 
                                                     
28
 In WEARIT study: 30%; In BIROAD study: 11%; 65 pts discontinuation due to comfort and lifestyle issues + 3pts discontinuation due to AEs 
29
 both occurred in patients who had incorrectly placed the therapy electrodes-one of the events was nonfatal as the patient received a successful external defibrillation 
30
 Occurred in a patient who removed the leads 
31
 pt experienced numerous false alarms “thus revealed reduced compliance to WCD wearing (16.3 h/day)” 
32
 6 pts due to discomfort and other reasons plus 7 pts due to unknown/other reasons 
33
 due to ECG artefacts while none due to induced VT/VF 
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Table 8: List of ongoing studies with WCD 
Study Identifier Estimated  
completion date 
Study type Number  
of patients 
Intervention Comparator Patient population Endpoints 
NCT01446965 December 2017 RCT 
(name: VEST 
study) 
2300 LifeVest® Conventional 
treatment 
Pts with ventricular 
dysfunction immediately 
following MI 
1) Sudden death mortality 
2) Cardiovascular, all-cause, and other 
cause specific mortality, incidence of 
VAs, AEs, compliance 
NCT02481206 October 2019 RCT 
(name:  
WED-HED) 
2600 LifeVest® Conventional 
Treatment 
End Stage Renal  
Disease pts beginning 
haemodialysis 
1) SCA mortality 
2) Total mortality, clinical status of SCA 
survivors, Incidence of potentially life 
threatening arrhythmias, risk of 
inappropriate therapy, compliance, QoL 
NCT01326624 March 2016 
No study results 
posted in 
ClinicalTrials.gov 
register 
Prospective  
Cohort  
(name:  
SWIFT study) 
25 LifeVest® - Pts with left ventricular 
dysfunction or 
advanced heart failure 
symptoms (NYHA 
Class III/IV) 
1) Defibrillation for life-threatening VT, 
assess magnitude and complexity of 
ventricular and atrial arrhythmias during 
use 
2) Total mortality, compliance, QoL, 
complications (AEs) 
NCT02825966 March 2016 
No study results 
posted in 
ClinicalTrials.gov 
register 
Prospective 
observational 
study 
(name: HS-WCD) 
35 LifeVest® - Pts (age ≥ 18 years) 
with at least seven pts 
> 40 years. At least five 
pts with a history of 
heart failure. 
1) Heart sounds 
NCT02816047 December 2016 Retrospective 
Cohort  
(Pt registry) 
450 LifeVest® - Comprehensive registry 
including all pts in all 
Austrian centers who 
received a WCD in 
2010-2016. 
Number of participants treated with 
WCD-treated VAs 
List of ongoing and planned studies 
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NCT02700880 June 2018  
(Estimated primary 
completion date) 
Prospective  
Cohort  
(name:  
WEARIT III  
registry) 
1000 LifeVest® 
4000 
- Pts with ischaemic 
cardiomyopathy and 
heart failure (including 
NYHA II, III, IV and an 
ejection fraction ≤ 35%) 
1) Number of clinical events 
2) All-cause mortality, Number of  
inappropriate shocks, WCD shock  
conversion success rate, NYHA  
functional class 
NCT02073942 December 2017 Prospective 
Case-only  
(Pt registry) 
(name: CRWD) 
100 WCD - Adult pts with an 
indication for WCD 
1) Number of arrhythmic events and 
arrhythmic risk factors 
2) Total mortality, QoL, depression, 
anxiety 
NCT02149290 December 2016 Prospective  
case-only 
(name: TRENDS) 
200 Trends-
equipped 
LifeVest® 
4000 
- Pts with heart failure 
who are being cared  
for in an outpatient 
environment 
1) Precision of heart failure metrics 
measurements 
2) Pt interactions with the Trends user 
interface, Pt interactions with the  
wearable defibrillator 
ISRCTN91372291 February 2018 Prospective  
registry 
550 LifeVest® - Pts who have been 
prescribed LifeVest® 
treatment in clinical 
routine 
1) Success rate of appropriate shocks 
2) Use of LifeVest® in pts at high risk for 
SCA in clinical practice, amount of 
inappropriate shocks, pt safety, 
compliance, factors influencing non-
compliance, circumstances associated 
with withdrawal of LifeVest®, technical 
malfunctions and misuses 
DRKS00005653 NA Prospective  
registry  
(WEARIT II  
Europe) 
700 WCD - All pts to whom the 
WCD will be prescribed 
during clinical routine 
1) incidence of life-threatening VT events, 
success of cardioversion/defibrillation, 
short-term outcome and clinical 
development 
2) Evaluate the 1-year outcome of pts 
after they have started to use the WCD 
NCT01448005 October 2014 
Study (enrollment) 
terminated. No study 
results posted in 
ClinicalTrials.gov 
register 
Multi-center  
prospective 
registry 
69 LifeVest® - Pts with an ejection 
fraction (EF) ≤ 35% 
following CABG  
surgery 
1) number of pts who experience SCD 
2) number of pts who experience 
inappropriate shocks, hours per day of 
WCD use, number of pts who 
experience SCA 
Abbreviations: AE-Adverse Events; ECG-Electrocardiogram; CABG-Coronary Artery Bypass Grafting; EF-Ejection Fraction; QoL-Quality of Life; MI-Myocardial Infarction; pt-patient; RCT-Randomised 
Controlled Trial; SAEs-serious adverse events; SCA-Sudden Cardiac Arrest; VT-Ventricular Tachycardia; WCD-Wearable Cardioverter Defibrillator. 
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Risk of bias tables 
 
Table 9: Risk of Bias – on study level 
 
Interventional 
single arm study 
Prospective  
case series 
Prospective  
registry studies 
Study  
reference/ID 
Feldman,  
2004 
[18] 
Duncke
r, 2014  
[19] 
Kondo, 
2015 
[20] 
Kao,  
2012 
[21] 
Kutyifa, 
2015 
[22] 
1. Is the hypothesis/aim/objective of the 
study stated clearly in the abstract, 
introduction, or methods section? 
Yes Yes Yes Yes Yes 
2. Are the characteristics of the participants 
included in the study described? 
Yes Yes Yes Yes Yes 
3. Were the cases collected in more than 
one centre? 
Yes No No Yes Yes 
4. Are the eligibility criteria (inclusion and 
exclusion criteria) for entry into the study 
explicit and appropriate?34 
Yes Partially 
reported 
Partially 
reported 
Yes Partially 
reported 
5. Were participants recruited 
consecutively? 
No Yes Yes No No 
6. Did participants enter the study at 
similar point in the disease?35 
Unclear Yes Yes No Unclear 
7. Was the intervention clearly described 
in the study? 
Yes Yes Partially 
reported36 
Yes Yes 
8. Were additional interventions  
(co-interventions) clearly reported in  
the study?37 
Unclear Yes Unclear Yes Unclear 
9. Are the outcome measures clearly 
defined in the introduction or methods 
section? 
Yes Yes No Yes Yes 
10. Were relevant outcomes appropriately 
measured with objective and/or 
subjective methods?38 
Unclear Unclear Unclear Unclear Unclear 
11. Were outcomes measured before and 
after intervention? 
No39 Yes Yes Yes Yes 
12. Were the statistical tests used to 
assess the relevant outcomes appropriate? 
Yes Yes Yes Yes Yes 
13. Was the length of follow-up reported? No Yes Yes Yes Yes 
14. Was the loss to follow-up reported? Yes Yes No Yes No 
15. Does the study provide estimates of 
the random variability in the data analysis 
of relevant outcomes? 40 
Partially  
reported 
Partially 
reported 
Partially 
reported 
Partially 
reported 
Partially 
reported 
                                                     
34
 “Partially reported”: Only inclusion criteria mentioned 
35
 “Unclear”: There is no statement about entering the study at a similar point in the disease 
36
 “Partially reported”: Intervention is only mentioned by name 
37
 “Unclear”: It is suspected that a co-intervention was administered but the information is not reported 
38
 “Unclear”: No information is provided on the methods used to measure study´s relevant outcomes 
39
 One relevant outcome was only measured before the intervention. Other relevant outcomes could have 
only been measured after the intervention. 
40
 “Partially reported”: Estimates of the random variability are not reported for all relevant outcomes. 
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Interventional 
single arm study 
Prospective  
case series 
Prospective  
registry studies 
Study  
reference/ID 
Feldman,  
2004 
[18] 
Duncke
r, 2014  
[19] 
Kondo, 
2015 
[20] 
Kao,  
2012 
[21] 
Kutyifa, 
2015 
[22] 
16. Are adverse events reported?41 Yes Partially 
reported 
Partially 
reported 
Partially 
reported 
Partially 
reported 
17. Are the conclusions of the study 
supported by results? 
Yes Yes Partially 
reported42 
No43 Yes 
18. Are both competing interest and 
source of support for the study 
reported?44 
Partially  
reported 
Yes Partially 
reported 
Yes Yes 
Overall Risk of bias High High Very high High High 
 
 
                                                     
41
 “Partially reported”: It is deducible that only some but not all potential adverse effects are reported. 
42
 Vague conclusion that does not sum up results. 
43
 No conclusion provided. 
44
 “Partially reported”: Only one of these elements is reported. 
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Table 10: GRADE assessment – on outcome level 
Outcome 
Trial 
R
is
k 
o
f b
ia
s 
In
co
n
si
st
en
cy
 
In
di
re
c
tn
es
s 
Im
pr
ec
is
io
n
 
O
th
er
 
co
n
si
de
ra
tio
n
s Qu
a
lit
y 
Im
po
rt
an
ce
 
Adverse Events (AE) 
Skin rash and itching   
1(289pts) 
[18] 
Very 
serious45 
NA Serious Serious46 None Very low Important 
False Alarms   
1 (12pts) 
[19] 
Serious NA Serious Very serious46,47 None Very low Critical 
Palpitations, light-headedness, and fainting 
  
1 (89pts) 
[21] 
Very 
serious48 
NA Serious Serious 46  None Very low Important 
Discontinuation due to comfort and lifestyle issues 
  
2 (378pts) 
[18, 21] 
Serious49 Serious Serious  Serious46 None Very low Critical 
Serious Adverse Events (SAE) 
Inappropriate shocks 
  
5 (2414pts) 
[18-22] 
Serious Serious Serious Serious46 None Very low Critical 
Unsuccessful shocks 
  
4 (2325pts) 
[18-20, 22] 
Serious Serious Serious Serious46 None Very low Critical 
Frequency of SAEs leading to death 
  
5 (2414pts) 
[18-22] 
Serious50 Serious Serious  Serious None Very low Critical 
Abbreviations: NA – not applicable 
                                                     
45
 No definition of skin rash/itching (severity, nature, location etc.) provided. No comparison group, patients 
not consecutively recruited. No data gathered on psychological issues, eating habits etc. Unclear whether 
additional interventions have been performed (which could have caused side effects). 
46
 Few events; no control group.  
47
 Very low sample size 
48
 Pts not consecutively recruited; no control group. No definition of nature and severity. 
49
 Pts in both studies not consecutively recruited. Pts might have been different with regard to confounding 
factors  
50
 Since no control group – cannot make statement on mortality 
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Applicability tables 
 
Table 11: Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population Study population represented a diverse spectrum of patients at risk for SCA. The reason 
being that indications for LifeVest® are manifold (see scope) and risk factors for SCA are 
not well defined and might vary based on and within the respective indication. The target 
population of the intervention did not differ from the population enrolled in clinical studies, 
but the trials did not include patients immediately after explantation of an ICD, if an 
immediate reimplantation of an ICD was not possible, or patients with certain forms of 
structural heart disease associated with risk of malignant arrhythmias or primary electric 
disease. 
Intervention WCD/LifeVest® was used autonomously by patients outside of the hospital in all included 
studies. 
Comparators  ICD (No comparative studies were available.) 
 GL directed pharmacological therapy (No comparative studies were available.) 
 GL directed catheter (radiofrequency) ablation (No comparative studies were 
available.) External defibrillators to be used in 3 settings: home, public places, and/or 
used by medical emergency staff during resuscitation (No comparative studies were 
available.) 
Outcomes Safety outcomes that were most frequently reported in the five studies were discontinuation 
due to comfort and lifestyle issues, inappropriate shocks, unsuccessful shocks, and frequency 
of SAEs leading to death. Skin rash/itching, false alarms, palpitations, light-headedness, and 
fainting were only reported in one study each. The outcomes measured reflect the most 
important SAEs associated with WCD/LifeVest®. 
Setting The studies included were either single-centre or multi-centre studies enrolling patients in 
Germany and the United States. Clinical settings were not described in any of the studies. 
However, it is likely that all patients received-standard care at university hospitals or cardiac 
units. Therefore, it can be assumed that the setting of the studies reflects the clinical setting 
in which the technology is intended to be used. It needs to be stated that patients are 
introduced to the technology in the hospital at the beginning and then the technology is 
used outside of the hospital, yet the patients are monitored throughout. 
Abbreviations: GL-Guideline; ICD-implantable cardioverter defibrillator; SAE-Serious Adverse Event; SCA-Sudden  
Cardiac Arrest; WCD-wearable cardioverter defibrillator. 
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APPENDIX 2: REGULATORY AND REIMBURSEMENT STATUS 
 
Table 12: Regulatory status of the technology 
Country 
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n
u
m
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r  
(if 
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ai
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bl
e) 
Counties 
where CE 
mark is 
accepted 
(Notifying 
body is in 
Germany) 
DQS 
Med 
Yes The LifeVest® system  
is indicated for patients 
18 years of age and older 
who are at risk for sudden 
cardiac arrest. 
Being a 
candidate for 
or refusing an 
implantable 
defibrillator. 
Original 
Approval 
1999 
WCD 4000 
Approval 
2011 
Yes 285855 
United States FDA Yes The LifeVest® system  
is indicated for patients 
18 years of age and older 
who are at risk for sudden 
cardiac arrest. 
The LifeVest® system is 
indicated for patients under 
18 years of age who are 
at risk for sudden cardiac 
arrest. Patients must have 
a chest circumference of 
26 inches (66 centimeters) 
or greater and a weight of 
18.75 kilograms  
(41.3 pounds) or greater. 
Being a  
candidate for  
or refusing an 
implantable 
defibrillator. 
Chest 
circumference 
of less than 26 
inches (66cm) 
and a weight of 
18.75kg  
(41.3 pounds) 
or less. 
Original 
Approval 
2001 
WCD 4000 
Approval 
2009 
Yes P010030 
Australia TGA Yes The LifeVest® system  
is indicated for patients 
18 years of age and older 
who are at risk for sudden 
cardiac arrest. 
Being a  
candidate for  
or refusing an 
implantable 
defibrillator. 
2006 Yes 130613 
Israel MOH Yes The LifeVest® system  
is indicated for patients 
18 years of age and older 
who are at risk for sudden 
cardiac arrest. 
Being a  
candidate for  
or refusing an 
implantable 
defibrillator. 
2010 Yes NA 
Japan PMDA Yes The LifeVest® system  
is indicated for patients 
18 years of age and older 
who are at risk for sudden 
cardiac arrest. 
Being a  
candidate for  
or refusing an 
implantable 
defibrillator. 
2013 Yes 22500BZI00
017000 
Singapore HSA Yes The LifeVest® system  
is indicated for patients 
18 years of age and older 
who are at risk for sudden 
cardiac arrest. 
Being a  
candidate for  
or refusing an 
implantable 
defibrillator. 
2014 Yes DE0014998 
Canada Health 
Canad
a 
Yes The LifeVest® system  
is indicated for patients 
18 years of age and older 
who are at risk for sudden 
cardiac arrest. 
Being a  
candidate for  
or refusing an 
implantable 
defibrillator. 
2015 No, date 
of launch 
NA 
96006 
China CFDA Yes The LifeVest® system is 
indicated for patients  
18 years of age and older 
who are at risk for sudden 
cardiac arrest. 
Being a  
candidate for  
or refusing an 
implantable 
defibrillator. 
2016 No, date 
of launch 
NA 
20163212082 
Abbreviations: CFDA-China Food and Drug Administration; FDA-Food and Drug Administration; HAS-Health Sciences 
Authority; MOH-Ministry of Health; NA-not available; PMDA-Pharmaceuticals and Medical Devices Agency;  
TGA-Therapeutic Goods Administration. 
Sources: [5] 
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Table 13: Summary of reimbursement recommendations in European countries 
for the technology 
Country and  
issuing organisation 
e.g. G-BA, NICE 
Summary of reimbursement  
recommendations and restrictions 
Summary of reasons for recommen-
dations, rejections and restrictions 
France, HAS ICD explant; awaiting cardiac transplant; 
post-MI with low EF 
Therapeutic reason in the selected 
indications and public health reason 
due to severity of the pathology. 
Luxemburg, NA ICD explant; awaiting cardiac transplant; 
post-MI with low EF 
NA 
Switzerland, NA  as a temporary treatment measure,  
if ICD implantation is not immediately 
possible or in patients with a planned 
heart transplant and 
 at high risk for SCA, particularly when 
ventricular dysfunction, 
cardiomyopathy, status after MI, 
myocarditis, patients after surgical or 
percutaneous revascularization, a 
LVEF<36% 
NA 
For countries with indication specific reimbursement include only the recommendations  
for the indication under assessment 
Include a reference to any publically available guidance document 
Abbreviations: EF-ejection fraction; HAS-Haute Autorité des Santé; ICD-implantable cardioverter defibrillator;  
LVEF-left ventricular ejection fraction; MI-myocardial infarction; NA-Not available. 
Sources: [5] 
 
In April 2014, Haute Autorité de santé (HAS) in France performed an HTA on WCD 4000, in which 
they included one prospective study (as included in the current HTA [21]) but added retrospective 
studies as well [80, 82-84]. For Luxemburg and Switzerland, data from manufacturer’s submission 
file was used, but the assessments as such were not found in the systematic literature search or 
handsearch, and so no comparative data were retrieved. 
Table 14: Summary of recommendations in European countries for the technology 
in the indication under assessment  
Country Organisatio
n 
Summary of recommendations and 
restrictions 
Summary of reasons for 
recommendations and 
restrictions 
Germany GKV 
Spitzenverb
and [45] 
 explantation of an ICD, if an 
immediate reimplantation of an ICD is 
not possible,  
 when an immediate implantation of an 
ICD is indicated but not possible e.g. 
due to contraindications of an operation,  
 in patients with right atrial or right 
ventricular thrombus or tumour in 
whom an immediate implantation of 
an ICD is indicated but not possible  
NA 
United 
States 
(non-EU 
HTA) 
TEC – Blue 
Cross and 
Blue Shield 
[33] 
Not recommended The available evidence is insufficient 
to determine whether WCDs improve 
the net health outcome, or are as ben-
eficial as any established alternatives, 
when used as a bridge to permanent 
ICD implantation. There is no direct 
evidence in CTs to evaluate the 
efficacy of the WCD in comparison 
to usual treatment or alternatives. 
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Abbreviations: EU-European; GKV-“Interessenvertretung der gesetzlichen Kranken- und Pflegekassen”; HTA-health 
technology assessment; ICD-implantable cardioverter defibrillator; NA-not available; TEC-Technology Evaluation Center; 
WCD – wearable cardioverter defibrillator. 
Sources: [5] 
The technology evaluation centre of the Blue Cross and Blue Shield Association did an 
assessment on the WCD in November 2010, which took into account only two studies [18, 39], 
the remainder of included studies were RCTs of early ICD implantation for patients at high risk for 
VAs [61, 85, 86]. They concluded that the studies only focused on detection and abortion of 
VT/VF, not on its effect and stated that there is a lack of high-quality evidence [33]. 
 
 
WCD therapy for prevention of SCA 
Version 1.4, November 2016 EUnetHTA JA3 WP4  72 
APPENDIX 3: CHECKLIST FOR POTENTIAL ETHICAL, ORGANISATIONAL, 
PATIENT AND SOCIAL, AND LEGAL ASPECTS 
 
1. Ethical  
1.1. Does the introduction of the new technology and its potential 
use/non-use instead of the defined, existing comparator(s) give 
rise to any new ethical issues? 
Yes 
The use of WCD gives rise to ethical issues with respect to principles of beneficence and 
justice. That is because of its wide base of indications that, due to its marginal benefit and 
cost-effective reasons, cannot be all covered in practice. Also, the WCD can only be used  
by patients who can (mentally and physically) operate it (i.e. push the “false alarm button” if 
necessary, who wear it appropriately), and hence it prefers those who are cognitively  
better-off to begin with. 
1.2. Does comparing the new technology to the defined, existing 
comparators point to any differences that may be ethically 
relevant? 
Yes 
Ethically relevant differences between the WCD and its comparators depend on particular 
indications. Possible ethical issues may arise by comparing the standard medical therapy 
with WCD due to the increased number of serious AEs caused by the medical therapy. 
Further issues may arise by comparing the ICD to the WCD due to the ICD’s intrusion on 
bodily integrity that brings along more mortality related harms at the expense of the ICD’s 
better protection. 
2. Organisational  
2.1. Does the introduction of the new technology and its potential 
use/non-use instead of the defined, existing comparator(s) 
require organisational changes? 
Yes 
The introduction of the WCD requires training of doctors (i.e. briefing on how the WCD works, 
how the data can be monitored and evaluated etc.). Furthermore, the doctors might need to 
dedicate more time to the patients (e.g. extra time for reviewing the data) and so the patient/ 
doctor communication is enhanced. 
2.2. Does comparing the new technology to the defined,  
existing comparator(s) point to any differences that may be 
organisationally relevant? 
Yes 
Depending on the comparator, free capacity of hospital beds can be generated,  
less emergency ambulance calls needed. 
3. Patient and Social  
3.1. Does the introduction of the new technology and its potential 
use/non-use instead of the defined, existing comparator(s) give 
rise to any new social issues? 
Yes 
As the technology alters the person’s outlook, its use may lead to stigmatisation particularly 
in women, as the technology makes the chest area look unnatural. By comparing the WCD to 
best medical practices, it may cause a possible harm to bystanders which may be considered 
as a new social issue. 
3.2. Does comparing the new technology to the defined, existing 
comparator(s) point to any differences that may be socially 
relevant? 
Yes 
Compared to alternative interventions, the WCD allows patients to return home and 
participate in their social life sooner.  
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4. Legal   
4.1. Does the introduction of the new technology and its potential 
use/non-use instead of the defined, existing comparator(s) give 
rise to any legal issues? 
Yes 
Introduction of the new technology gives rise to legal issue concerning person’s rights and 
state’s duties that will presumably vary upon particular indications.  
Further legal issues with respect to responsibility and insurance may arise in situations of 
false shocks when delivered in inappropriate moments such as when driving a car. 
4.2. Does comparing the new technology to the defined, existing 
comparator(s) point to any differences that may be legally 
relevant? 
Yes 
Comparing the WCD to existing alternatives leads to legally relevant differences depending 
on particular indications. With reference to medical therapy, patients may claim their right to 
be treated by the WCD when faced with the option of medical therapy and its side effects. 
Patients may claim their right to be treated by the WCD when faced with the alternative of a 
surgical intervention that intrudes on their bodily integrity. Also, in particular settings with an 
elevated cultural perception of the notion of liability, patients may be themselves required to 
be legally responsible for wearing the WCD.  
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APPENDIX 4: ADDITIONAL TABLES AND FIGURES 
 
Table 15: Antiarrhythmic drugs for treatment of VT/VF [1] 
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Table 16: Non-invasive and invasive evaluation methods [1] 
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Figure 3: Diagnostic work-up [1] 
